CN103694236A - Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity - Google Patents
Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity Download PDFInfo
- Publication number
- CN103694236A CN103694236A CN201310463448.2A CN201310463448A CN103694236A CN 103694236 A CN103694236 A CN 103694236A CN 201310463448 A CN201310463448 A CN 201310463448A CN 103694236 A CN103694236 A CN 103694236A
- Authority
- CN
- China
- Prior art keywords
- alkane
- group
- synthetic
- follows
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 149
- 241000289669 Erinaceus europaeus Species 0.000 title claims abstract description 37
- 125000000714 pyrimidinyl group Chemical group 0.000 title claims abstract description 29
- 230000000694 effects Effects 0.000 title abstract description 14
- 239000005557 antagonist Substances 0.000 title abstract description 9
- 230000037361 pathway Effects 0.000 title abstract description 6
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims description 85
- 230000000259 anti-tumor effect Effects 0.000 claims description 79
- 229920006395 saturated elastomer Polymers 0.000 claims description 56
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 44
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 230000003042 antagnostic effect Effects 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 20
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- -1 azido- Chemical class 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 10
- 125000003375 sulfoxide group Chemical group 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- QBPFLGQMJZOZIV-UHFFFAOYSA-N oxourea Chemical group NC(=O)N=O QBPFLGQMJZOZIV-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 238000005096 rolling process Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 229940022353 herceptin Drugs 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 229960003685 imatinib mesylate Drugs 0.000 claims description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 229960001320 lapatinib ditosylate Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 150000003956 methylamines Chemical class 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 102000035160 transmembrane proteins Human genes 0.000 abstract description 10
- 108091005703 transmembrane proteins Proteins 0.000 abstract description 10
- 241000027355 Ferocactus setispinus Species 0.000 abstract description 8
- 230000008929 regeneration Effects 0.000 abstract description 7
- 238000011069 regeneration method Methods 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 6
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 230000000903 blocking effect Effects 0.000 abstract description 2
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 293
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 168
- 239000007787 solid Substances 0.000 description 136
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 126
- 239000012071 phase Substances 0.000 description 92
- 238000004440 column chromatography Methods 0.000 description 84
- 238000007670 refining Methods 0.000 description 83
- 238000005481 NMR spectroscopy Methods 0.000 description 75
- 239000012074 organic phase Substances 0.000 description 71
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 58
- 238000001035 drying Methods 0.000 description 58
- 239000000243 solution Substances 0.000 description 58
- 239000003921 oil Substances 0.000 description 57
- 238000006243 chemical reaction Methods 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 238000010189 synthetic method Methods 0.000 description 49
- 238000010183 spectrum analysis Methods 0.000 description 47
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 46
- 238000003756 stirring Methods 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
- 238000013019 agitation Methods 0.000 description 45
- 230000006837 decompression Effects 0.000 description 45
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 43
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 42
- 239000000463 material Substances 0.000 description 39
- 239000011780 sodium chloride Substances 0.000 description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- 239000000047 product Substances 0.000 description 35
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 239000007864 aqueous solution Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 238000003810 ethyl acetate extraction Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000003809 water extraction Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000004237 preparative chromatography Methods 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000012827 research and development Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RZDKHKXBRIBDIN-UHFFFAOYSA-N tert-butyl 2-oxopiperidine-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1CCNC(=O)C1 RZDKHKXBRIBDIN-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
- 229960004449 vismodegib Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- OWQUYBAASOSGNO-CDNKMLFNSA-N 2-[[(Z)-N-(2-hydroxy-5-sulfoanilino)-C-phenylcarbonimidoyl]diazenyl]benzoic acid Chemical compound C1=CC=C(C=C1)/C(=N/NC2=C(C=CC(=C2)S(=O)(=O)O)O)/N=NC3=CC=CC=C3C(=O)O OWQUYBAASOSGNO-CDNKMLFNSA-N 0.000 description 1
- JHGGKVFEGBEWQR-UHFFFAOYSA-N 2-bromo-3,5-dimethylpyridine Chemical compound CC1=CN=C(Br)C(C)=C1 JHGGKVFEGBEWQR-UHFFFAOYSA-N 0.000 description 1
- PZSISEFPCYMBDL-UHFFFAOYSA-N 2-bromo-3-methylpyridine Chemical compound CC1=CC=CN=C1Br PZSISEFPCYMBDL-UHFFFAOYSA-N 0.000 description 1
- YWNJQQNBJQUKME-UHFFFAOYSA-N 2-bromo-5-methylpyridine Chemical compound CC1=CC=C(Br)N=C1 YWNJQQNBJQUKME-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- QKJAZPHKNWSXDF-UHFFFAOYSA-N 2-bromoquinoline Chemical compound C1=CC=CC2=NC(Br)=CC=C21 QKJAZPHKNWSXDF-UHFFFAOYSA-N 0.000 description 1
- GELVZYOEQVJIRR-UHFFFAOYSA-N 2-chloropyrazine Chemical compound ClC1=CN=CC=N1 GELVZYOEQVJIRR-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- OWJZYAWGVTYNGX-UHFFFAOYSA-N CCOc1nc(CCN(C2)c(nc3)cc(-c4c(C)cc(C)cn4)c3Cl)c2cn1 Chemical compound CCOc1nc(CCN(C2)c(nc3)cc(-c4c(C)cc(C)cn4)c3Cl)c2cn1 OWJZYAWGVTYNGX-UHFFFAOYSA-N 0.000 description 1
- FTYWBMJILROJNE-UHFFFAOYSA-N Cc(cc1C)cnc1-c(cc(N(CC1)Cc2c1nc(NC)nc2)nc1)c1Cl Chemical compound Cc(cc1C)cnc1-c(cc(N(CC1)Cc2c1nc(NC)nc2)nc1)c1Cl FTYWBMJILROJNE-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 101001074046 Xenopus laevis Zinc finger protein GLI1 Proteins 0.000 description 1
- 101001008944 Xenopus tropicalis Kinesin-like protein KIF11 Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- HFXKQSZZZPGLKQ-UHFFFAOYSA-N cyclopentamine Chemical compound CNC(C)CC1CCCC1 HFXKQSZZZPGLKQ-UHFFFAOYSA-N 0.000 description 1
- 229960003263 cyclopentamine Drugs 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940043798 zincon Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity, which comprises compound and pharmaceutically acceptable salt thereof, various isotopes, various isomers or various crystal structures, and the product comprises the structure shown in the general formula I: wherein, X is a five-membered or six-membered aromatic ring, heteroaromatic ring and heterocyclic ring, and substituted derivatives thereof. The novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity provided by the invention can block transmembrane protein acceptor SMO, and block hedgehog pathway Hedgehog, thereby inhibiting abnormal growth of cells, blocking migration and regeneration of tumor cells with obvious antineoplastic effect.
Description
Technical field
The present invention relates to medical technical field, relate in particular to the new antitumoral compounds that a kind of pyrimidine skeleton has hedgehog path antagonistic activity.
Background technology
Malignant tumour is one of main disease of harm humans health, the annual malignant tumour new cases approximately 1,090 ten thousand in the whole world, and every year because of the dead patient approximately 6,700,000 [1] of malignant tumour, therefore, the key subjects of control Yi Shi the world of medicine of tumour, wherein the research and development of antitumor drug are explored huge variation have been occurred through years of researches; With antitumor drug conventional on preclinical therapy, be mainly cytotoxic drug, this class antitumour drug has poor selectivity, toxic side effect and by force, easily produces the shortcomings such as resistance; In recent years along with the progress at full speed of life science, progressively being illustrated of the various primary processes such as interaction of the signal transduction in malignant cell, the regulation and control of cell cycle, apoptotic induction, vasculogenesis and cell and extracellular matrix, using the key enzyme of some intracellular signal transduction pathway relevant to tumour cell differentiation and proliferation as drug screening target spot, selectively acting, in these specific target spots, possesses the important directions that pilot compound efficient, low toxicity character has become current antitumor drug research and development simultaneously; The successful listing of the targeted drugs such as Herceptin (trastuzumab), imatinib (imatinib), Gefitinib (gefitinib) and erlotinib (erlotinib) is exactly typical example [2].
Shifting with regeneration is the feature of malignant tumour, is also a difficult problem for treatment malignant tumour, even the targeted drug of a new generation is also very micro-with regeneration curative effect to the transfer of tumour.Based on this; the research of Hedgehog (Hh) signal path-hedgehog path has in recent years been subject to scientific circles and has more and more paid attention to; this is not only because Hh signal path abnormal activation comprises that in many tumours the generation evolution of rodent cancer, cerebral tumor, mammary cancer, prostate cancer and some alimentary system malignant tumours has all played very important effect [3-11]; the more important thing is that Hh signal path is fetal development path; to regulation and control tumor stem cell, thereby control metastases and regeneration play an important role.
Hedgehog signal path is the intercellular signal transduction system of a high conservative, within 1980, in fruit bat, find, because can causing larva body surface, this pathway gene sudden change of fruit bat reveals the furcellas of many likeness in form hedgehogs, therefore called after hedgehog path Hedgehog (Hh) [12].Hh signal path forms [13] by Hh part, two transmembrane protein acceptor patched membrane receptor (PTCH) and smoothened transmembrane protein (SMO) and downstream transcription factor Gli albumen etc.PTCH and SMO are two kinds of transmembrane proteins that are positioned on target cell membrane, and wherein PTCH is 12 transmembrane proteins of being encoded by cancer suppressor gene PTCH, is a kind of cell surface receptor, have the dual function of isolation and transduction Hh; SMO is 7 transmembrane proteins, and structure Shang Yu g protein coupled receptor family is highly similar, has the effect of transduction Hh signal.PTCH and SMO play the effect of acceptor in Hh signal transduction process, the acceptor that wherein PTCH is Hh, and when not there is not Hh, PTCH stops SMO to insert to cytolemma, thereby suppresses the activity of SMO, and then suppresses the transcriptional expression of downstream gene; When Hh signal exists, Hh is combined with PTCH, a plurality of serine/threonine residue generation phosphorylations of induction SMO carboxyl terminal, cause SMO assemble and activate at cell surface, the SMO activating and kinesin sample molecule Costal2 (Cos2) and serine/threonine kinases fused (Fus), Suppressor offused (Sufu) form mixture and dissociate out from microtubule, form performance transcriptional activation with total length, finally cause that zinc refers to sample transcription factor Gli activation, and the latter enters and in nucleus, causes transcribing of target gene.Therefore, in Hh signal path, Hh is the starting point of this signal path, and Gli is the terminal of this signal path as transcription factor, and Hh and SMO are as the exciting factor, and PTCH, as supressor, is regulating and controlling the activity [12,14] of signal path.
Transmembrane protein acceptor SMO is as the key members of Hh signal path, it is the transcriber in Hh signal path, it can convert intracellular Gli1 signal to extracellular Hh signal, thereby active cell core is intragentic, transcribes, and Hh signal path is had to activation [15].Most and Hh cell pathway activate the functional sudden change that all exists SMO in the generation, evolution of relevant tumour cell.Small molecules SMO protein antagonist is specific inhibition Hh signal path by antagonism SMO, and Hh signal path at normal adult in inactivated state, so antagonist can not have side effects to other positions of body, this is the theoretical basis of the magnetic target therapy feasibility of tumour.Therefore, SMO albumen has become one of target spot attracting people's attention most in current antitumor drug research and development, the synthetic research and development focus of Ge great drugmaker in the world that also becomes of the small molecular antagonists of target SMO albumen.
Have at least now the small molecular antagonists (comprising following three compounds) of 5 target SMO albumen carrying out clinical trial, the small molecules SMO antagonist GDC-0449 of the common research and development of U.S. Genentech company and Curis company, the treatment [16] for rodent cancer patient in late period by the FDA of U.S. food Drug Administration approval in January, 2012.This proof small molecules SMO antagonist has good using value and market outlook as the research and development of anti-cancer agent.
Reference
1.Jemal,A.;Siegel,R.;Weingerg.R.A.Cancer?statistics,2010.CA..Cancer?J.Cli.,2010,144,277-300.
2.Workman,P.;Collins,I.Modern?Cancer?Drug?Discovery:Integrating?Targets,Technologies?and?Treatments.In?Cancer?Drug?Design?and?Discovery,1st?ed.;Neidle,S.,Ed.;Elsevier:New?York,2008;pp3-38.
3.di?Magliano,M.P.;Hebrok,M.Hedgehog?signalling?in?cancer?formation?and?maintenance.Nat.Rev.Cancer2003,3,903–911.
4.Beachy,P.A.;Karhadkar,S.S.;Berman,D.M.Tissue?repair?and?stem?cell?renewal?in?carcinogenesis.Nature?2004,432,324–331.
5.Dahmane,N.;Lee,J.;Robins,P.;Heller,P.;Ruizi?Altaba,A.Activation?of?the?transcription?factor?Gli1?and?the?sonic?Hedgehog?signaling?pathway?in?skin?tumours.Nature?1997,389,876–881.
6.Hutchin,M.E.;Kariapper,M.S.T.;Gratchtchouk,M.;Wang,A.;Wei,L.;Cummings,D.;Liu,J.;Michael,L.R.;Glick,A.;Dlugosz,A.A.Sustained?Hedgehog?signaling?is?required?for?basal?cell?carcinoma?proliferation?and?survival:Conditional?skin?tumorigenesis?recapitulates?the?hair?growth?cycle.Genes?Dev.2004,19,214–224.
7.Kubo,M.;Nakamura,M.;Tasaki,A.;Yamanaka,N.;Nakashima,H.;Nomura,M.;Kuroki,S.;Katano,M.Hedgehog?signaling?pathway?is?a?new?therapeutic?target?for?patients?with?breast?cancer.Cancer?Res.2004,64,6071–6074.
8.Berman,D.M.;Karhadkar,S.S.;Maitra,A.;Montes?de?Oca,R.;Gerstenblith,M.R.;Briggs,K.;Parker,A.R.;Shimada,Y.;Eshleman,J.R.;Watkins,D.N.;Beachy,P.A.Widespread?requirement?for?Hedgehog?ligand?stimulation?in?growth?of?digestive?tract?tumors.Nature?2003,425,846–851.
9.Goodrich,L.V.;Scott,M.P.Hedgehog?and?Patched?in?neural?development?and?disease.Neuron?1998,21,1243–1257.
10.Stecca,B.;Mas.,C.;Clement,V.;Zbinden,M.;Correa,R.;Piguet,V.;Beermann,F.;Ruiz,A.Melanomas?require?Hedgehog-Gli?signaling?regulated?by?interactions?between?Gli1?and?the?RAS-MEK/AKT?pathways.Proc.Natl.Acad.Sci.U.S.A.2007,104,5895–5900.
11.Thayer,S.P.;Pasca?di?Magliano,M.;Heiser,P.W.;Nielsen,C.M.;Roberts,D.J.;Lauwers,G.Y.;Qi,Y.P.;Gysin,S.;Fernandez-del?Castillo,C.;Yajnik,V.;Antoniu,B.;McMahon,M.;Warshaw,A.L.;Hebrok,M.Hedgehog?is?an?early?and?late?mediator?of?pancreatic?cancer?tumorigenesis.Nature?2003,425,851–856.
12.Lum,L.;Beachy,P.A.The?Hedgehog?response?network:sensors,witches,and?routers.Science?2004,304,1755–1759.
13.Beachy,P.A.;Karhadkar,S.S.;Berman,D.M.Tissue?repair?and?stem?cell?renewal?in?carcinogenesis.Nature?2004,432,324–331.
14.Pasca?di?Magliano,M.;Hebrok,M.Hedgehog?signalling?in?cancer?formation?and?maintenance.Nat.Rev.Cancer?2003,3,903–911.
15.Romer,J.T.;Kimura,H.;Magdaleno,S.;Sasai,K.;Fuller,C.;Baines,H.;Connelly,M.;Stewart,C.F.;Gould,S.;Rubin,L.L.;Curran,T.Suppression?of?the?Shh?pathway?using?a?small?molecule?inhibitor?eliminates?medulloblastoma?in?Ptc1(+/-)p53(-/-)mice.Cancer?Cell?2004,6,229–240.
16.Curis?Pharmaceuticals?press?release:
http://investors.curis.com/releasedetail.cfm?ReleaseID=643756
Summary of the invention
Defect in view of above-mentioned prior art existence, the object of the invention is to propose a kind of new antitumoral compounds of blocking the pyrimidine skeleton of transmembrane protein acceptor SMO, can block hedgehog path Hedgehog, thereby suppress cellular abnormality, increase, blocking-up tumour cell shifts regeneration.
Object of the present invention is achieved by the following technical programs:
Pyrimidine skeleton has a new antitumoral compounds for hedgehog path antagonistic activity, comprises this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, has the structure shown in general formula I:
Wherein, X is five yuan or hexa-atomic aromatic nucleus, fragrant heterocycle, heterocycle, and the substitutive derivative n of described ring is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, preferably, this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, comprise general formula I I or general formula III structure:
Wherein: A is nitrogen-atoms or C-R7, n is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, preferred:
Described alkyl is alkyl or the substituted hydrocarbon radical of saturated straight chain, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described thiazolinyl is alkyl or the substituted hydrocarbon radical of the straight chain that contains at least one carbon-carbon double bond, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described alkynyl is alkyl or the substituted hydrocarbon radical of the straight chain, side chain, ring-type, double-ring or the Spirocyclic that contain at least one carbon carbon triple bond of 1-10 carbon atom composition;
The substituting group of the monocycle that described fragrant cyclic group is aromaticity, many rings or heterocyclic substituent and substitutive derivative thereof, and the cyclic substituents derivative with saturated rings;
Described heterocyclic radical is monocycle, dicyclo, three ring or the volution substituting groups of the nonaromatic combination that comprises an atom in nitrogen, oxygen and sulphur or a plurality of atoms, and the cyclic substituents of their various oxidation state;
The described substituting group containing heteroatom functional group is the halogeno-group containing F, Cl, Br or I or the substituting group that comprises the one or more atoms in nitrogen, oxygen, sulphur and phosphorus, and their various oxidation state, and the quaternary ammonium salt of nitrogen.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, preferably, described R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, alkyl, thiazolinyl, alkynyl, fragrant cyclic group or heterocyclic radical that hydrogen atom is replaced by halogeno-group, cyano group, amino, hydroxyl, sulfydryl, alkoxyl group, ester group, sulfuryl, sulfoxide group, sulfahydantoin or azido-, and cyclic alkyl, ring-type thiazolinyl, 3-12 unit's heterocyclic radical or 5-12 membered aromatic heterocycle base; The alkyl that described hydrogen atom is replaced by halogeno-group is preferably trifluoromethyl.
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, the structure of substituent X is any one in lower array structure, wherein between pentacyclic structure and between the structure of six-ring, is respectively bioequivalence body:
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, it comprises following compounds, and pharmacy acceptable salt, various isotropic substance, various isomer or various crystalline structure:
Above-mentioned a kind of pyrimidine skeleton has in the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, the methylamino in compound or substituted methylamine base replace with any one in following amine and analogue thereof:
Above-mentioned a kind of pyrimidine skeleton has the new antitumoral compounds of hedgehog path antagonistic activity, and preferred, it comprises following compound:
The present invention also provides a kind of antitumor medicine composition, comprises the combination that at least two kinds of compounds in new antitumoral compounds, its pharmacy acceptable salt, various isotropic substance, various isomer or the various crystalline structure that the above-mentioned pyrimidine skeleton with formula I structure has hedgehog path antagonistic activity form.
The present invention also provides a kind of combined utilization composition of antitumor drug, this combined utilization composition be above-mentioned pyrimidine skeleton have the new antitumoral compounds of hedgehog path antagonistic activity and pharmaceutical composition thereof respectively with cis-platinum, taxol, camptothecine, Herceptin, imatinib mesylate, imatinib, Gefitinib, erlotinib, lapatinibditosylate in one or more combination carry out the composition that combined utilization obtains.
The application of the combined utilization composition that the present invention also provides new antitumoral compounds, antitumor medicine composition or antitumor drug that above-mentioned pyrimidine skeleton has hedgehog path antagonistic activity in the medicine of preparation treatment tumour, described tumour comprises liver cancer, lung cancer, the rectum cancer, cervical cancer, cancer of pancreas, breast cancer, cancer of the stomach, oral carcinoma, the esophageal carcinoma, nasopharyngeal carcinoma, skin carcinoma, osteocarcinoma, the combination of one or more in kidney and leukemia.
Outstanding effect of the present invention is: a kind of pyrimidine skeleton of the present invention has the new antitumoral compounds of hedgehog path antagonistic activity, by blocking-up transmembrane protein acceptor SMO, can block hedgehog path Hedgehog, thereby suppress cellular abnormality, increase, blocking-up tumour cell shifts regeneration.
Below, the specific embodiment of the present invention is described in further detail, so that technical solution of the present invention is easier to understand, grasp just in conjunction with the embodiments.
embodiment
Below by specific embodiment, method of the present invention is described, but the present invention is not limited thereto.Experimental technique described in following embodiment, if no special instructions, is ordinary method; Described reagent and material, if no special instructions, all can obtain from commercial channels.Solvent for use and medicine are analytical pure or chemical pure; Solvent all passes through re-distillation before use; Anhydrous solvent is all processed according to standard method or literature method.Column chromatography silica gel (100-200 order) and tlc silica gel (GF254) are Haiyang Chemical Plant, Qingdao and chemical plant, Yantai product; If not otherwise specified, all adopt sherwood oil (60-90 ℃)/ethyl acetate (v/v) as eluent; The ethanolic soln of iodine or phospho-molybdic acid for developer; All extraction solvent unexplained reference are all used anhydrous Na
2sO
4dry.Bruck-400 type nuclear magnetic resonance analyser record for 1H-NMR, TMS is interior mark.U.S. Agilent company 1100 type HPLC-ESI-MSn combined instrument (LC-MSD Trap) records for LC-MS, diode-array detector (DAD), detects wavelength 214nm and 254nm, ion trap mass spectrometry (ESI source).HPLC post is Agela Durashell C18 (4.6 * 50mm, 3.5 μ m); Moving phase is 0.1%NH
4hCO
3the aqueous solution: acetonitrile (in 5 minutes from 5: 95 to 95: 5); Flow velocity is 1.8mL/min.
Embodiment 1
The present embodiment provides a kind of new antitumoral compounds A1, and the synthetic method of this compound is as follows:
1) intermediate A 1-2's is synthetic:
By in the molten 40 milliliters of DMFs of 4-tertbutyloxycarbonyl piperidone (10g, 50.2mmol), add while stirring DMF dimethylacetal (6g, 50mmol), finish, 80 ℃ are reacted 12 hours.Be cooled to room temperature, join in ethyl acetate (150mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) washes twice, and anhydrous sodium sulfate drying filters, and revolves and steams to such an extent that an orange crude product (13g) is directly cast single step reaction.
2) intermediate A 1-3's is synthetic:
Under normal temperature, by sulfuric acid half methyl-thiourea (6.98g, 25.1mmol) and sodium ethylate (3.28g, 40mmol) be dissolved in 40 milliliters of ethanol, stir after half an hour, add step synthetic intermediate A 1-2(13g, 50.2mmol) 10 milliliters of ethanolic solns, backflow 12h, be cooled to room temperature, underpressure distillation, enriched material washes with water, ethyl acetate extraction, organic phase is washed with saturated common salt, after anhydrous sodium sulfate drying filters, and evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: methylene dichloride=1:25) an orange (7.38g, 52%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.24 (s, 1H), 4.50 (s, 2H), 3.69 (t, J=5.9Hz, 2H), 2.86 (t, J=5.8Hz, 2H), 2.52 (s, 3H), 1.47 (s, 9H).
3) intermediate A 1-4's is synthetic:
By A1-3(7.38g, 26.3mmol) after being dissolved in 50 milliliters of methylene dichloride of 0 ℃, slowly add while stirring metachloroperbenzoic acid (75%, 12.5g, 54.5mmol), after stirring at normal temperature 12 hours, the saturated aqueous solution (10mL) that adds sodium bicarbonate (10mL) and Sulfothiorine, stirring at normal temperature 2h, organic phase underpressure distillation is concentrated, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1) a white solid (5.5g, 67%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.63 (s, 1H), 4.70 (s, 2H), 3.79 (t, J=5.9Hz, 2H), 3.33 (s, 3H), 3.09 (t, J=5.8Hz, 2H), 1.49 (s, 9H).
4) intermediate A 1-5's is synthetic:
A1-4(1g, 3.19mmol) and methylamine alcohol solution (21%, 1mL) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (700mg, 83%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.03 (s, 1H), 4.41 (s, 2H), 3.67 (t, J=5.8Hz, 2H), 3.52 (s, 3H), 2.73 (t, J=5.7Hz, 2H), 1.56 (s, 9H).
5) intermediate A 1-6's is synthetic:
By A1-5(700mg, 2.65mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins in saturated sodium bicarbonate aqueous solution in (5 milliliters) and methylene dichloride (20 milliliters), saturated aqueous common salt for organic phase (5mL) is washed, anhydrous sodium sulfate drying is spin-dried for to obtain a white solid (420mg, 96%) after filtering.
6) intermediate A 1-9's is synthetic:
By 2, the chloro-4-boric acid of 5-bis-pyridine (7.56g, 40mmol) He 3,5-dimethyl-2-bromopyridine (5.62g, 30mmol) joins in the mixed solution of 60 milliliters of dioxane and 12 ml waters, then adds Pd(dppf) Cl2(1.35g, 1.7mmol) He three water potassiumphosphate (16.2g, 60mmol), nitrogen exchange three times for reaction system, reflux is spent the night.Reaction solution cool to room temperature, adds 50 ml waters to filter, and filtrate extracts three times with methylene dichloride (50mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: product ethyl acetate=10:1) (3.1g, 41%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.46 (s, 1H), 8.37 (s, 1H), 7.47 (s, 1H), 7.33 (s, 1H), 2.39 (s, 3H), 2.16 (s, 3H).
7) product A 1 is synthetic:
A1-6 (100mg, 0.610mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (45mg, 60%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.11 (s, 1H), 7.43 (s, 1H), 6.65 (s, 1H), 4.54 (s, 2H), 3.90 (s, 2H), 3.00 (d, J=5.0Hz, 3H), 2.88 (s, 2H), 2.37 (s, 3H), 2.17 (s, 3H); ESI-MS (m/z): 380.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 2
The present embodiment provides a kind of new antitumoral compounds A2, and the synthetic method of this compound is as follows:
1) intermediate A 2-1's is synthetic:
A1-4(1g, 3.19mmol) and ethylamine solution (71%, 1mL) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (400mg, 45%).
2) intermediate A 2-2's is synthetic:
By A2-1(400mg, 1.44mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), and saturated aqueous common salt for organic phase (10mL) is washed, after filtering, anhydrous sodium sulfate drying obtains a white solid (250mg, 97%).
3) product A 2 is synthetic:
A2-2 (100mg, 0.562mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (25mg, 32%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.34 (s, 1H), 8.22 (s, 1H), 8.08 (s, 1H), 7.41 (s, 1H), 6.63 (s, 1H), 4.52 (s, 2H), 3.89 (t, J=5.6Hz, 2H), 3.47-3.37 (m, 2H), 2.85 (t, J=5.8Hz, 2H), 2.36 (s, 3H), 2.16 (s, 3H), 1.21 (t, J=7.2Hz, 3H); ESI-MS (m/z): 394.9[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 3
The present embodiment provides a kind of new antitumoral compounds A3, and the synthetic method of this compound is as follows:
1) intermediate A 3-1's is synthetic:
A1-4(1g, 3.19mmol) and cyclopropylamine (300mg, 5.26mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (460mg, 50%).
2) intermediate A 3-2's is synthetic:
By A3-1(460mg, 1.58mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and enriched material joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), and saturated aqueous common salt for organic phase (10mL) is washed, after filtering, anhydrous sodium sulfate drying obtains a white solid (270mg, 90%).
3) product A 3 is synthetic:
A3-2 (100mg, 0.345mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (30mg, 40%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.39 (s, 1H), 8.23 (s, 1H), 8.17 (s, 1H), 7.42 (s, 1H), 6.65 (s, 1H), 4.55 (s, 2H), 3.90 (t, J=5.6Hz, 2H), 2.88 (t, J=5.8Hz, 2H), 2.77 (m, 1H), 2.42 (s, 3H), 2.21 (s, 3H), 1.29 (s, 1H), 0.87-079 (m, 2H), 0.62-0.55 (m, 2H); ESI-MS (m/z): 406.9[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 4
The present embodiment provides a kind of new antitumoral compounds A4, and the synthetic method of this compound is as follows:
1) intermediate A 4-1's is synthetic:
A1-4(1g, 3.19mmol) and Pyrrolidine (300mg, 4.22mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (600mg, 62%).
2) intermediate A 4-2's is synthetic:
By A4-1(600mg, 1.97mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), saturated aqueous common salt for organic phase (10mL) is washed, with anhydrous sodium sulfate drying, after filtering and concentrating, obtain a white solid (360mg, 89%).
3) product A 4 is synthetic:
A4-2 (100mg, 0.490mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (37mg, 47%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 4.51 (s, 2H), 3.89 (t, J=5.6Hz, 2H), 3.56 (t, J=6.5Hz, 4H), 2.89 (t, J=5.8Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.97 (t, J=6.6Hz, 4H); ESI-MS (m/z): 420.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 5
The present embodiment provides a kind of new antitumoral compounds A5, and the synthetic method of this compound is as follows:
1) intermediate A 5-1's is synthetic:
A1-4(1g, 3.19mmol) with N-methyl 2-monoethanolamine (480mg, 6.39mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (280mg, 28%).
2) intermediate A 5-2's is synthetic:
By A5-1(280mg, 0.91mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), and saturated aqueous common salt for organic phase (10mL) is washed, after filtering, anhydrous sodium sulfate drying obtains a white solid (180mg, 95%).
3) product A 5 is synthetic:
A5-2 (80mg, 0.384mmol), cesium fluoride (50mg, 0.329mmol) and A1-9(50mg, 0.198mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (20mg, 24%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.33 (s, 1H), 8.21 (s, 1H), 8.08 (s, 1H), 7.41 (s, 1H), 6.63 (s, 1H), 4.51 (s, 2H), 3.87 (s, 4H), 3.74 (s, 2H), 3.19 (s, 3H), 2.86 (s, 2H), 2.35 (s, 3H), 2.15 (s, 3H); ESI-MS (m/z): 424.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 6
The present embodiment provides a kind of new antitumoral compounds A6, and the synthetic method of this compound is as follows:
1) intermediate A 6-1's is synthetic:
A1-4(1g, 3.19mmol) with 4-hydroxy piperidine (650mg, 6.39mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=2:1) a white solid (400mg, 37.5%).
2) intermediate A 6-2's is synthetic:
By A6-1(400mg, 1.2mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), saturated aqueous common salt for organic phase (10mL) is washed, with anhydrous sodium sulfate drying, after filtering and concentrating, obtain a white solid (210mg, 79%).
3) product A 6 is synthetic:
A6-2 (200mg, 0.85mmol), cesium fluoride (300mg, 1.98mmol) and A1-9(80mg, 0.31mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (30mg, 21%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.37 (s, 1H), 8.24 (s, 1H), 8.12 (s, 1H), 7.47 (s, 1H), 6.66 (s, 1H), 4.53 (s, 2H), 4.43 (s, 2H), 3.40 (s, 3H), 3.31 (s, 2H), 2.89 (s, 2H), 2.39 (s, 3H), 2.25 (s, 3H), 1.94 (s, 2H), 1.55 (s, 2H); ESI-MS (m/z): 450.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 7
The present embodiment provides a kind of new antitumoral compounds A7, and the synthetic method of this compound is as follows:
1) intermediate A 7-1's is synthetic:
A1-4(1g, 3.19mmol) and morpholine (700mg, 8.0mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=2:1) a white solid (760mg, 75%).
2) intermediate A 7-2's is synthetic:
By A7-1(700mg, 2.3mmol) be dissolved in after a small amount of methylene dichloride, the saturated ethyl acetate solution (3mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins saturated sodium bicarbonate aqueous solution and washes in (5mL) and methylene dichloride (20mL), saturated aqueous common salt for organic phase (10mL) is washed, with anhydrous sodium sulfate drying, after filtering and concentrating, obtain a white solid (434mg, 83%).
3) product A 7 is synthetic:
A6-2 (50mg, 0.23mmol), cesium fluoride (300mg, 1.98mmol) and A1-9(20mg, 0.079mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (10mg, 29%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.40 (s, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 7.52 (s, 1H), 6.69 (s, 1H), 4.56 (s, 2H), 3.91 (s, 3H), 3.78-3.78 (m, 8H), 2.90 (s, 2H), 2.41 (s, 3H), 2.21 (s, 3H); ESI-MS (m/z): 436.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 8
The present embodiment provides a kind of new antitumoral compounds A8, and the synthetic method of this compound is as follows:
1) intermediate A 8-1's is synthetic:
A1-4(854mg, 2.728mmol) and 2,6-lupetazin (950mg, 8.333mmol) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, and through column chromatography, refining (moving phase is sherwood oil: ethyl acetate=5:1 to methylene dichloride to enriched material: methyl alcohol=10:1) must a white solid (245mg, 26.5%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 7.97 (s, 1H), 4.54 (d, J=13.2Hz, 2H), 4.33 (s, 2H), 3.59 (s, 2H), 2.67 (s, 2H), 2.38-2.29 (m, 2H), 1.97 (s, 2H), 1.41 (s, 9H), 1.06 (d, J=6.0Hz, 6H).
2) intermediate A 8-2's is synthetic:
By A8-1(245mg, 0.706mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a yellow solid (100mg, 57.3%).
3) product A 8 is synthetic:
A8-2 (90mg, 0.364mmol), cesium fluoride (43mg, 0.283mmol) and A1-9(31mg, 0.123mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (36mg, 63.4%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.29 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 7.36 (s, 1H), 6.59 (s, 1H), 4.82-4.59 (m, 2H), 4.48 (s, 2H), 3.84 (t, J=5.2Hz, 2H), 3.08 (s, 4H), 2.82 (t, J=6.0Hz, 2H), 2.31 (s, 3H), 2.11 (s, 3H), 1.50 (s, 6H); ESI-MS (m/z): 463.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 9
The present embodiment provides a kind of new antitumoral compounds A9, and the synthetic method of this compound is as follows:
1) intermediate A 9-1's is synthetic:
A1-4(1g, 3.195mmol) with methylethylolamine solution (27%-32%, 1g) be under agitation dissolved in successively in ethanol (10mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material obtains a yellow oil (500mg, 59.3%) through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1 is to 1:1).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.03 (s, 1H), 4.40 (s, 2H), 4.10 (q, J=7.1Hz, 1H), 3.67 (t, J=5.6Hz, 2H), 2.97 (d, J=5.2Hz, 3H), 2.73 (t, J=5.6Hz, 2H), 1.47 (s, 9H).
2) intermediate A 9-2's is synthetic:
A9-1 (300mg, 1.14mmol) is dissolved in the methylene dichloride of 10mL, at 0 ℃, adds triethylamine (487mg, 4.82mmol), dropwise add subsequently methylene dichloride (5mL) solution of methylsulfonyl chloride (360mg, 3.16mmol).At 0 ℃, stir 1 hour, desolventizing is revolved in decompression, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a colorless oil (321mg, 82.7%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.23 (s, 1H), 4.46 (s, 2H), 3.65 (t, J=5.8Hz, 2H), 3.43 (s, 3H), 3.40 (s, 3H), 2.82 (t, J=5.6Hz, 2H), 1.41 (s, 9H).
3) intermediate A 9-3's is synthetic:
By A9-2(321mg, 0.94mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a white solid (76mg, 33.5%).Its chemical shift is as follows:
1h-NMR (400MHz, DMSO-d6) δ 8.20 (s, 1H), 3.99 (s, 2H), 3.45 (s, 3H), 3.42 (s, 3H), 3.24 (t, J=6.4Hz, 2H), 2.89 (t, J=5.8Hz, 2H).
4) product A 9 is synthetic:
A9-3 (76mg, 0.364mmol), cesium fluoride (64mg, 0.42mmol) and A1-9(53mg, 0.21mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (3 mg, 3.1%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.33 (s, 1H), 8.31 (s, 1H), 8.19 (s, 1H), 7.47 (s, 1H), 6.66 (s, 1H), 4.62 (s, 2H), 3.88 (t, J=5.6Hz, 2H), 3.47 (s, 3H), 3.44 (s, 3H), 2.97 (t, J=5.6Hz, 2H), 2.35 (s, 3H), 2.15 (s, 3H); ESI-MS (m/z): 458.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 10
The present embodiment provides a kind of new antitumoral compounds A10, and the synthetic method of this compound is as follows:
1) intermediate A 10-1's is synthetic:
Pyrazoles (435mg, 6.4mmol) is dissolved in the tetrahydrofuran (THF) of 15mL, at 0 ℃, adds sodium hydride (80%, 221mg, 7.36mmol), at room temperature stir 15 minutes, then add A1-4 (1g, 3.2mmol), stir 1 hour at 0 ℃.Add saturated aqueous ammonium chloride cancellation, desolventizing is revolved in decompression, add methylene dichloride (150mL) and water (100mL), after organic phase is filtered with anhydrous sodium sulfate drying, revolve desolventizing, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=1:1) a white solid (610mg, 63.4%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.52 (s, 1H), 8.40 (s, 1H), 7.76 (s, 1H), 6.43 (s, 1H), 4.57 (s, 2H), 3.72 (t, J=5.8Hz, 2H), 2.99 (t, J=5.6Hz, 2H), 1.45 (s, 9H).
2) intermediate A 10-2's is synthetic:
By A10-1 (610mg, 2.03mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a white solid (173mg, 42.5%).
3) product A 10 is synthetic:
A10-2 (140mg, 0.70mmol), cesium fluoride (70mg, 0.46mmol) and A1-9(59mg, 0.23mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (22mg, 22.6%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.56 (s, 1H), 8.51 (s, 1H), 8.38 (s, 1H), 8.25 (s, 1H), 7.80 (s, 1H), 7.52 (s, 1H), 6.74 (s, 1H), 6.47 (s, 1H), 4.76 (s, 2H), 3.97 (s, 2H), 3.16 (s, 2H), 2.40 (s, 3H), 2.20 (s, 3H); ESI-MS (m/z): 417.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 11
The present embodiment provides a kind of new antitumoral compounds A11, and the synthetic method of this compound is as follows:
1) intermediate A 11-1's is synthetic:
A1-4(625mg, 2mmol) and Isopropylamine (2g, 33.9mmol) be under agitation dissolved in successively in the trimethyl carbinol (15mL), be heated to reflux, after 36 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material obtains a yellow solid (365mg, 62.6%) through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1 is to 1:1).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 7.97 (s, 1H), 4.75 (d, J=7.2Hz, 1H), 4.35 (s, 2H), 4.04 (m, 1H), 3.61 (t, J=5.2Hz, 2H), 2.66 (s, 2H), 1.42 (s, 9H), 1.16 (d, J=6.4Hz, 6H).
2) intermediate A 11-2's is synthetic:
By A11-1(365mg, 1.25mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a yellow solid (157mg, 65.4%).
3) product A 11 is synthetic:
A11-2 (147mg, 0.77mmol), cesium fluoride (78mg, 0.51mmol) and A1-9(65mg, 0.255mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (24mg, 22.9%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 7.43 (s, 1H), 6.64 (s, 1H), 4.93 (d, J=7.6Hz, 1H), 4.53 (s, 2H), 4.13 (m, 1H), 3.90 (s, 2H), 2.84 (t, J=5.6Hz, 2H), 2.36 (s, 3H), 2.18 (s, 3H), 1.23 (d, J=6.4Hz, 6H); ESI-MS (m/z): 408.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 12
The present embodiment provides a kind of new antitumoral compounds A12, and the synthetic method of this compound is as follows:
1) intermediate A 12-1's is synthetic:
In tube sealing by A1-4(1g, 3.2mmol) and TERTIARY BUTYL AMINE (1.4g, 19.2mmol) be dissolved in successively in the trimethyl carbinol (15mL), be heated to 80 ℃, after 54 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a yellow oil (130mg, 13.3%).
1H-NMR(400MHz,CDCl
3)δ7.97(s,1H),4.98(s,1H),4.37(s,2H),3.65(s,2H),2.68(s,2H),1.45(s,9H),1.39(s,9H)。
2) intermediate A 12-2's is synthetic:
By A12-1(130mg, 0.42mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a yellow oil (43mg, 52.4%).
3) product A 12 is synthetic:
A12-2 (43mg, 0.21mmol), cesium fluoride (32mg, 0.21mmol) and A1-9(27mg, 0.105mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (15mg, 33.3%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.06 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 5.15 (s, 1H), 4.51 (s, 2H), 3.88 (t, J=5.2Hz, 2H), 2.84 (t, J=5.8 Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.43 (s, 9H); ESI-MS (m/z): 422.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 13
The present embodiment provides a kind of new antitumoral compounds A13, and the synthetic method of this compound is as follows:
1) intermediate A 13-1's is synthetic:
By A1-4(1g, 3.2mmol) be dissolved in the aniline of 10mL, be heated to 100 ℃, after 48 hours, be cooled to room temperature, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=8:1) a brown oil (280mg, 26.9%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.17 (s, 1H), 7.63 (s, 1H), 7.61 (s, 1H), 7.35 (s, 1H), 7.33 (s, 1H), 7.31 (s, 1H), 4.49 (s, 2H), 3.73 (t, J=5.8Hz, 2H), 2.84 (t, J=5.8Hz, 2H), 1.50 (s, 9H).
2) intermediate A 13-2's is synthetic:
By A13-1(280mg, 0.86mmol) join the hydrogenchloride ethyl acetate solution (3mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a brown solid (140mg, 72.2%).
3) product A 13 is synthetic:
A13-2 (80mg, 0.35mmol), cesium fluoride (81mg, 0.53mmol) and A1-9(45mg, 0.178mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (26mg, 33.1%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.41 (s, 1H), 8.26 (d, J=5.2Hz, 2H), 7.64 (s, 1H), 7.62 (s, 1H), 7.55 (s, 1H), 7.34 (t, J=7.2Hz, 2H), 7.06 (t, J=7.8Hz, 1H), 6.73 (s, 1H), 4.63 (s, 2H), 3.95 (s, 2H), 3.01 (t, J=5.4Hz, 2H), 2.42 (s, 3H), 2.22 (s, 3H); ESI-MS (m/z): 442.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 14
The present embodiment provides a kind of new antitumoral compounds A14, and the synthetic method of this compound is as follows:
1) intermediate A 14-1's is synthetic:
By A1-3(1g, 3.56mmol) join the hydrogenchloride ethyl acetate solution ethyl acetate solution (5mL) of 3M, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, enriched material joins in saturated sodium bicarbonate aqueous solution (5mL) and methylene dichloride (20mL), after organic phase is concentrated with anhydrous sodium sulfate drying Guo Lv ﹑, obtain a brown oil (600mg, 93.2%).
2) product A 14 is synthetic:
A14-1 (480mg, 2.65mmol), cesium fluoride (808mg, 5.32mmol) and A1-9(335mg, 1.33mmol) under agitation condition, be dissolved in methyl-sulphoxide (7mL) respectively, be heated to 120 ℃, react 12 hours.Be cooled to room temperature, add ethyl acetate (100mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow oil (270mg, 50.9%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.38 (s, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 7.48 (s, 1H), 6.70 (s, 1H), 4.67 (s, 2H), 3.93 (t, J=5.1Hz, 2H), 3.01 (t, J=5.4Hz, 2H), 2.56 (s, 3H), 2.40 (s, 3H), 2.20 (s, 3H); ESI-MS (m/z): 397.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 15
The present embodiment provides a kind of new antitumoral compounds A15, and the synthetic method of this compound is as follows:
By A14(320mg, 0.81mmol) be dissolved in the tetrahydrofuran (THF) of 10mL, peroxosulphuric hydrogen potassium (546mg, 1.78 mmol) is dissolved in the water of 2mL.Two solution are merged, stir and spend the night at normal temperatures.Add ethyl acetate (100mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) is washed, and anhydrous sodium sulfate drying revolves desolventizing after filtering, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow oil (150mg, 43.2%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.69 (s, 1H), 8.35 (s, 1H), 8.25 (s, 1H), 7.44 (s, 1H), 6.74 (s, 1H), 4.87 (s, 2H), 3.97 (t, J=5.6Hz, 2H), 3.35 (s, 3H), 3.22 (t, J=5.8Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H); ESI-MS (m/z): 429.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 16
The present embodiment provides a kind of new antitumoral compounds A16, and the synthetic method of this compound is as follows:
By A15(40mg, 0.093mmol) with cyclopropyl methylamine (14mg, 0.197mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (15.2mg, 38.9%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 7.42 (s, 1H), 6.64 (s, 1H), 5.16 (t, J=6.0Hz, 1H), 4.52 (s, 2H), 3.89 (t, J=5.0Hz, 2H), 3.25 (t, J=6.2Hz, 2H), 2.86 (t, J=5.4Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.07 (m, 1H), 0.51 (d, J=7.6Hz, 2H), 0.24 (d, J=4.8Hz, 2H); ESI-MS (m/z): 420.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 17
The present embodiment provides a kind of new antitumoral compounds A17, and the synthetic method of this compound is as follows:
By A15(44mg, 0.103mmol) with 3-pyrrolidinol (36mg, 0.414mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (7.4mg, 16.5%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.34 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.42 (s, 1H), 6.64 (s, 1H), 4.57 (s, 1H), 4.51 (s, 2H), 3.89 (t, J=5.2Hz, 2H), 3.73-3.62 (m, 2H), 2.88 (t, J=5.8Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 2.13-2.01 (m, 2H); ESI-MS (m/z): 436.8[M+1]
+.
The oily matter of gained is through resolving to
Embodiment 18
The present embodiment provides a kind of new antitumoral compounds A18, and the synthetic method of this compound is as follows:
By A15(40mg, 0.093mmol) and sodium ethylate (19mg, 0.279mmol) be dissolved in the ethanol of 2mL, at 0 ℃, react 1 hour, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (20mg, 54.3%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.43 (s, 1H), 6.67 (s, 1H), 4.64 (s, 2H), 4.39 (q, J=7.2Hz, 2H), 3.91 (s, 2H), 2.98 (t, J=5.6Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H), 1.42 (t, J=7.1Hz, 3H); ESI-MS (m/z): 395.9[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 19
The present embodiment provides a kind of new antitumoral compounds A19, and the synthetic method of this compound is as follows:
By A15 (40mg, 0.093mmol), 4-methoxyl group piperidine hydrochlorate (29mg, 0.186mmol) and triethylamine (21mg, 0.205mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (7.5mg, 17.4%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.37 (s, 1H), 8.24 (s, 1H), 8.11 (s, 1H), 7.44 (s, 1H), 6.65 (s, 1H), 4.52 (s, 2H), 4.32 (d, J=6.0Hz, 2H), 3.90 (s, 2H), 3.45 (m, 1H), 3.40 (s, 3H), 3.38-3.34 (m, 2H), 2.87 (s, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.93-1.93 (m, 2H), 1.61-1.54 (m, 2H); ESI-MS (m/z): 464.8[M+1]
+.
The oily matter spectrum analysis of gained is
Embodiment 20
The present embodiment provides a kind of new antitumoral compounds A20, and the synthetic method of this compound is as follows:
At 0 ℃, sodium hydride (80%, 9mg, 0.28mmol) is joined in the Virahol of 5mL, keep 0 ℃ of reaction 15 minutes, then by A15(40mg, 0.093mmol) join in reaction solution, keep 0 ℃ of reaction 2h, add saturated ammonium chloride solution cancellation, desolventizing is revolved in decompression, and enriched material dilutes by ethyl acetate, family's saturated common salt washing, organic phase is dry concentrated, through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (18mg, 47.4%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 5.26 (m, 1H), 4.64 (s, 2H), 3.91 (s, 2H), 2.98 (s, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.38 (d, J=4.4Hz, 6H); ESI-MS (m/z): 409.8[M+1]
+.
The oily matter spectrum analysis of gained is
Embodiment 21
The present embodiment provides a kind of new antitumoral compounds A21, and the synthetic method of this compound is as follows:
By A15(44mg, 0.10mmol) and cyclopentamine (27mg, 0.31mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, and desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (4.2mg, 9.4%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.33 (s, 1H), 8.21 (s, 1H), 8.07 (s, 1H), 7.40 (s, 1H), 6.62 (s, 1H), 5.13 (d, J=8.8Hz, 1H), 4.50 (s, 2H), 4.23 (m, 1H), 3.87 (t, J=5.8Hz, 2H), 2.83 (t, J=5.8Hz, 2H), 2.35 (s, 3H), 2.15 (s, 3H), 2.05-1.98 (m, 2H), 1.70-1.61 (m, 4H), 1.48-1.41 (m, 2H); ESI-MS (m/z): 434.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 22
The present embodiment provides a kind of new antitumoral compounds A22, and the synthetic method of this compound is as follows:
By cyclopentanol (27mg, 0.31mmol) join in the tetrahydrofuran (THF) of 2mL, at 0 ℃, add sodium hydride (80%, 10mg, 0.33mmol), keep 0 ℃ of reaction 15 minutes, again by A15(43mg, 0.10mmol) join in reaction solution, keep 0 ℃ of reaction 2h, use saturated ammonium chloride solution cancellation, desolventizing is revolved in decompression, add water 30mL, by ethyl acetate (30mL * 3), extract, after organic phase is filtered with anhydrous sodium sulfate drying, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (2.3mg, 5.2%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.28 (s, 1H), 8.25 (s, 1H), 7.44 (s, 1H), 6.68 (s, 1H), 5.41 (m, 1H), 4.65 (s, 2H), 3.92 (t, J=5.0Hz, 2H), 2.99 (t, J=5.6Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.98-1.95 (m, 2H), 1.88 (s, 2H), 1.63 (s, 4H); ESI-MS (m/z): 435.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 23
The present embodiment provides a kind of new antitumoral compounds A23, and the synthetic method of this compound is as follows:
By A15 (42mg, 0.098mmol), 3-hydroxyl azetidine hydrochloride (55mg, 0.5mmol) and triethylamine (60mg, 0.205mmol) be dissolved in the trimethyl carbinol of 2mL, be heated to 80 ℃, reaction is spent the night, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (6.9mg, 16.8%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.24 (s, 1H), 8.13 (s, 1H), 7.43 (s, 1H), 6.65 (s, 1H), 4.86-4.67 (m, 1H), 4.54 (s, 2H), 4.39 (t, J=8.0Hz, 2H), 3.99-3.96 (m, 2H), 3.90 (t, J=5.6Hz, 2H), 2.90 (t, J=6.0Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H); ESI-MS (m/z): 422.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 24
The present embodiment provides a kind of new antitumoral compounds A24, and the synthetic method of this compound is as follows:
By cyclopropyl-carbinol (72mg, 1mmol) join in the tetrahydrofuran (THF) of 2mL, at 0 ℃, add sodium hydride (80%, 33mg, 1.1mmol), keep 0 ℃ of reaction 15 minutes, again by A15(44mg, 0.103mmol) join in reaction solution, normal-temperature reaction 3h, use saturated ammonium chloride solution cancellation, desolventizing is revolved in decompression, add water 30mL, by ethyl acetate (30mL * 3), extract, after organic phase is filtered with anhydrous sodium sulfate drying, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil (2.8mg, 6.5%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 7.44 (s, 1H), 6.68 (s, 1H), 4.65 (s, 2H), 4.18 (d, J=7.6Hz, 2H), 3.92 (t, J=4.6Hz, 2H), 2.99 (t, J=5.6Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.32 (m, 1H), 0.61 (d, J=7.2Hz, 2H), 0.37 (d, J=4.8Hz, 2H); ESI-MS (m/z): 421.9[M+1]
+.
The oily matter spectrum analysis of gained is
Embodiment 25
The present embodiment provides a kind of new antitumoral compounds A25, and the synthetic method of this compound is as follows:
1) intermediate A 25-1's is synthetic:
4-tertbutyloxycarbonyl piperidone (1g, 5.0mmol) is dissolved in anhydrous tetrahydro furan, and at nitrogen protection borehole cooling, to-78 ℃, lithium diisopropyl amido (3mL, 6.0mmol) is added drop-wise in above-mentioned solution at this temperature; After 30 minutes, methyl iodide (852mg, 6.0mmol) adds at-78 ℃, and reaction at room temperature continues to stir 3 hours.With saturated aqueous ammonium chloride solution cancellation, add ethyl acetate (20mL) extraction, organic phase is revolved desolventizing after filtering with anhydrous sodium sulfate drying, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=20:1) a colourless oil liquid (500mg, 45.5%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 4.11 (m, 1H), 3.71 (m, 1H), 3.23 (m, 1H), 2.81 (br s, 1H), 2.47 (m, 3H), 1.47 (s, 9H), 1.03 (d, J=6.8Hz, 3H).
2) intermediate A 25-2's is synthetic:
By A25-1(200mg, 0.94mmol) molten 2 milliliters of DMF dimethylacetals, finish, 80 ℃ are reacted 12 hours.Be cooled to room temperature, revolve and steam to such an extent that an orange crude product is directly cast single step reaction.Under normal temperature, by sulfuric acid half methyl-thiourea (88mg, 0.47mmol) and sodium ethylate (64mg, 0.94mmol) be dissolved in 4 milliliters of ethanol, stir after half an hour, 1 milliliter of the ethanolic soln that adds the synthetic orange crude product of step, backflow 12h, is cooled to room temperature, underpressure distillation, enriched material dilute with water, ethyl acetate extraction, organic phase is washed with saturated common salt, after anhydrous sodium sulfate drying filters, evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:5) an orange (100mg, 36%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.25 (s, 1H), 3.75-3.70 (m, 3H), 3.49 (m, 1H), 2.94 (m, 1H), 2.56 (s, 3H), 1.41 (s, 9H), 1.26 (t, J=7.2Hz, 3H).
3) intermediate A 25-3's is synthetic:
By A25-2(900mg, 3.1mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (450mg, 74%) and be directly used in next step with reversed-phase preparative chromatography.
4) product A 25 is synthetic:
A25-3 (450mg, 2.3mmol), cesium fluoride (700mg, 4.6mmol) and A1-9(580mg, 2.3mmol) under agitation condition, be dissolved in methyl-sulphoxide (2.5mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (450mg, 48%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.31 (s, 1H), 8.24 (s, 1H), 7.44 (s, 1H), 6.67 (s, 1H), 4.63 (m, 2H), 3.99 (m, 1H), 3.58 (m, 1H), 3.12 (m, 1H), 2.57 (s, 3H), 2.38 (s, 3H), 2.18 (s, 3H), 1.38 (d, J=5.0Hz, 3H); ESI-MS (m/z): 411.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 26
The present embodiment provides a kind of new antitumoral compounds A26, and the synthetic method of this compound is as follows:
1) intermediate A 26-1's is synthetic:
By A25(50mg, 0.12mmol) be dissolved in the mixed solvent of tetrahydrofuran (THF) and water, in ice-water bath, add potassium hydrogen persulfate (72mg, 0.24mmol), reaction at room temperature continues to stir 16 hours, remove by filter not tolerantly, filtrate concentrated post (methylene dichloride: methyl alcohol=50:1) purifying obtains product (10mg, 19%).
2) compd A 26 is synthetic:
A26-1(20mg, 0.045mmol) and cyclopropylamine (5.1mg, 0.09mmol) be under agitation dissolved in successively in the trimethyl carbinol (1mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=50:1) a yellow solid (8mg, 42%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.34 (s, 1H), 8.22 (s, 1H), 8.15 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 5.21 (s, 1H), 4.53 (s, 2H), 3.92 (m, 1H), 3.59 (m, 1H), 2.95 (m, 1H), 2.21 (m, 1H), 2.37 (s, 3H), 2.17 (s, 3H), 1.32 (d, J=6.8Hz, 3H), 0.87-079 (m, 2H), 0.58-0.52 (m, 2H); ESI-MS (m/z): 443.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 27
The present embodiment provides a kind of new antitumoral compounds A27, and the synthetic method of this compound is as follows:
A26-1(20mg, 0.045mmol) He 2,6-lupetazin (10.3mg, 0.09mmol) be under agitation dissolved in successively in the trimethyl carbinol (1mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=50:1) a yellow solid (7mg, 32.5%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.37 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.44 (s, 1H), 6.64 (s, 1H), 4.73 (m, 2H), 4.53 (m, 2H), 4.01 (m, 1H), 3.52 (m, 1H), 3.01 (br, 3H), 2.71 (br, 2H), 2.38 (s, 3H), 2.19 (s, 3H), 1.35-1.26 (m, 9H); ESI-MS (m/z): 477.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 28
The present embodiment provides a kind of new antitumoral compounds A28, and the synthetic method of this compound is as follows:
1) intermediate A 28-1's is synthetic:
By A25-2(2g, 6.8mmol) after being dissolved in 20 milliliters of methylene dichloride of 0 ℃, slowly add while stirring metachloroperbenzoic acid (75%, 3.16g, 13.6mmol), after stirring at normal temperature 12 hours, the saturated aqueous solution (5mL) that adds sodium bicarbonate (5mL) and Sulfothiorine, stirring at normal temperature 30 minutes, organic phase underpressure distillation is concentrated, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1) a white solid (1.5g, 67%).
2) intermediate A 28-2's is synthetic:
A28-1(250mg, 0.76mmol) and Pyrrolidine (216mg, 3.04mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (190mg, 78%).
3) intermediate A 28-3's is synthetic:
By A28-2(190mg, 0.6mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (110mg, 84%) and be directly used in next step with reversed-phase preparative chromatography.
4) product A 28 is synthetic:
A28-3 (67mg, 0.31mmol), cesium fluoride (96mg, 0.63mmol) and A1-9(78mg, 0.31mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a white solid (50 mg, 37%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.39 (s, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 7.46 (s, 1H), 6.66 (s, 1H), 4.54 (s, 2H), 4.02 (m, 1H), 3.61-3.58 (m, 5H), 3.05 (m, 1H), 2.41 (s, 3H), 2.11 (s, 3H), 2.01-1.99 (m, 4H), 1.37 (d, J=6.8Hz, 3H); ESI-MS (m/z): 434.9[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 29
The present embodiment provides a kind of new antitumoral compounds A29, and the synthetic method of this compound is as follows:
1) intermediate A 29-1's is synthetic:
A28-1(250mg, 0.76mmol) with 4-hydroxy piperidine (232mg, 2.3mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), be heated to reflux, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=1:1) a white solid (200mg, 75%).
3) intermediate A 29-2's is synthetic:
By A29-1(200mg, 0.57mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained white solid (100mg, 71%) and be directly used in next step with reversed-phase preparative chromatography.
3) product A 29 is synthetic:
A29-1 (77mg, 0.31mmol), cesium fluoride (96mg, 0.63mmol) and A1-9(78mg, 0.31mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a colorless oil, place in air and within 24 hours, change yellow solid into, purifying obtains white solid (10mg, 6.7%) again.Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.89 (s, 1H), 8.47 (s, 1H), 8.34 (s, 1H), 8.01 (s, 1H), 7.44 (s, 1H), 4.52-4.48 (m, 2H), 4.42-4.38 (m, 1H), 4.02-4.00 (m, 2H), 3.55-3.50 (m, 1H), 3.12-3.10 (m, 1H), 2.37 (s, 3H), 2.23 (s, 3H), 1.97 (m, 2H), 1.62 (m, 2H), 1.39 (d, J=6.8Hz, 3H); ESI-MS (m/z): 478.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 30
The present embodiment provides a kind of new antitumoral compounds A30, and the synthetic method of this compound is as follows:
1) intermediate A 30-1's is synthetic:
4-tertbutyloxycarbonyl piperidone (1g, 5.0mmol) is dissolved in anhydrous tetrahydro furan, and at nitrogen protection borehole cooling, to zero degree, sodium hydride (80%, 332mg, 11mmol) is added drop-wise in above-mentioned solution at this temperature; After 30 minutes, methyl iodide (1.56g, 11mmol) adds under zero degree, and reaction at room temperature continues to stir 3 hours.With saturated aqueous ammonium chloride solution cancellation, add ethyl acetate (20mL) extraction, organic phase is revolved desolventizing after filtering with anhydrous sodium sulfate drying, solute through column chromatography refining (moving phase is sherwood oil: ethyl acetate=20:1) a colourless oil liquid (600mg, 53%).
2) intermediate A 30-2's is synthetic:
By A30-1(7g, 31mmol) in molten 50 milliliters of DMFs, then add DMF dimethylacetal (7.4g, 62mmol), finish 80 ℃ of reactions 12 hours.Be cooled to room temperature, revolve and steam to such an extent that an orange crude product is directly cast single step reaction.Under normal temperature, by sulfuric acid half methyl-thiourea (4.3g, 15.4mmol) and sodium ethylate (2.1g, 31mmol) be dissolved in 80 milliliters of ethanol, stir after half an hour, 20 milliliters of ethanolic solns that add the synthetic orange crude product of step, backflow 12h, is cooled to room temperature, underpressure distillation, enriched material dilute with water, ethyl acetate extraction, organic phase is washed with saturated common salt, after anhydrous sodium sulfate drying filters, evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:5) a colorless oil (6g, 62%).
3) intermediate A 30-3's is synthetic:
By A30-2(200mg, 0.64mmol) be dissolved in 3M ethyl acetate solution (5mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (110mg, 82.5%) and be directly used in next step with reversed-phase preparative chromatography.
4) product A 30 is synthetic:
A30-3 (106mg, 0.51mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (62mg, 29%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.37 (s, 1H), 8.30 (s, 1H), 8.24 (s, 1H), 7.45 (s, 1H), 6.68 (s, 1H), 4.62 (s, 2H), 3.68 (s, 2H), 2.57 (s, 3H), 2.39 (s, 3H), 2.19 (s, 3H), 1.34 (s, 6H); ESI-MS (m/z): 425.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 31
The present embodiment provides a kind of new antitumoral compounds A31, and the synthetic method of this compound is as follows:
1) intermediate A 31-1's is synthetic:
By A30-2(5g, 16mmol) after being dissolved in 100 milliliters of methylene dichloride of 0 ℃, slowly add while stirring metachloroperbenzoic acid (85%, 5.6g, 32mmol), after stirring at normal temperature 12 hours, the saturated aqueous solution (20mL) that adds sodium bicarbonate (20mL) and Sulfothiorine, stirring at normal temperature 30 minutes, organic phase underpressure distillation is concentrated, through column chromatography refining (moving phase is sherwood oil: ethyl acetate=3:1) a white solid (2.5g, 46%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.62 (s, 1H), 4.74 (s, 2H), 3.56 (s, 2H), 3.41 (s, 3H), 1.50 (s, 9H), 1.40 (s, 6H).
2) intermediate A 31-2's is synthetic:
A31-1(400mg, 1.2mmol) and cyclopropylamine (342mg, 5mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (300mg, 79%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.24 (s, 1H), 4.47 (s, 2H), 3.44 (s, 2H), 2.74 (m, 1H), 1.49 (s, 9H), 1.25 (s, 6H), 0.79 (m, 2H), 0.52 (m, 2H).
3) intermediate A 31-3's is synthetic:
By A31-2(300mg, 0.94mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (200mg, 97%) and be directly used in next step with reversed-phase preparative chromatography.Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 7.99 (s, 1H), 5.17 (s, 1H), 3.86 (s, 2H), 2.89 (s, 2H), 2.73 (m, 1H), 1.25 (s, 6H), 0.75 (m, 2H), 0.53 (m, 2H).
4) product A 31 is synthetic:
A31-3 (111mg, 0.51mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (60mg, 27%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.24 (s, 1H), 8.19 (s, 1H), 7.44 (s, 1H), 6.64 (s, 1H), 5.38 (s, 1H), 4.53 (s, 2H), 3.65 (s, 2H), 2.68 (m, 1H), 2.38 (s, 3H), 2.19 (s, 3H), 1.30 (s, 6H), 0.81 (m, 2H), 0.55 (m, 2H); ESI-MS (m/z): 434.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 32
The present embodiment provides a kind of new antitumoral compounds A32, and the synthetic method of this compound is as follows:
1) intermediate A 32-1's is synthetic:
A31-1(150mg, 0.44mmol) and Pyrrolidine (156mg, 2.2mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is sherwood oil: ethyl acetate=4:1) a white solid (110mg, 75%).
2) intermediate A 32-2's is synthetic:
By A32-1(110mg, 0.33mmol) be dissolved in 3M ethyl acetate solution (5mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained white solid (60mg, 78%) and be directly used in next step with reversed-phase preparative chromatography.
3) product A 32 is synthetic:
A32-2 (47.6mg, 0.21mmol), cesium fluoride (64mg, 0.42mmol) and A1-9(54mg, 0.21mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (10mL) and water (5mL), saturated aqueous common salt for organic phase (5mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:100) a yellow solid (30mg, 32%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 7.43 (s, 1H), 6.63 (s, 1H), 4.50 (s, 2H), 3.66 (br s, 2H), 3.58 (br, 4H), 2.38 (s, 3H), 2.19 (s, 3H), 1.98 (m, 4H), 1.31 (s, 6H); ESI-MS (m/z): 448.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 33
The present embodiment provides a kind of new antitumoral compounds A33, and the synthetic method of this compound is as follows:
1) intermediate A 33-1's is synthetic:
A31-1(400mg, 1.2mmol) He 2,6-lupetazin (399mg, 3.6mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=25:1) a white solid (240mg, 53%).
2) intermediate A 33-2's is synthetic:
By A33-1(240mg, 0.64mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (130mg, 74%) and be directly used in next step with reversed-phase preparative chromatography.
3) product A 33 is synthetic:
A33-2 (130mg, 0.47mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51 mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:25) a yellow solid (65mg, 28%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.36 (s, 1H), 8.23 (s, 1H), 8.12 (s, 1H), 7.44 (s, 1H), 6.64 (s, 1H), 4.80-4.77 (m, 2H), 4.53 (br, 2H), 3.66 (s, 2H), 3.14 (br, 2H), 2.89 (m, 2H), 2.38 (s, 3H), 2.19 (s, 3H), 1.47 (d, J=5.2Hz, 6H), 1.31 (s, 6H); ESI-MS (m/z): 491.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 34
The present embodiment provides a kind of new antitumoral compounds A34, and the synthetic method of this compound is as follows:
1) intermediate A 34-1's is synthetic:
A31-1(400mg, 1.2mmol) with 4-hydroxy piperidine (360mg, 3.6mmol) be under agitation dissolved in successively in the trimethyl carbinol (2mL), heat 90 ℃, after 12 hours, be cooled to room temperature, desolventizing is revolved in decompression, enriched material through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=25:1) a white solid (200mg, 46%).
2) intermediate A 34-2's is synthetic:
By A34-1(200mg, 0.55mmol) be dissolved in 3M ethyl acetate solution (10mL), stirring at normal temperature 3 hours, filters.Filter cake is water-soluble adjusts PH=7.0 with saturated aqueous sodium carbonate, and solution is purified and obtained yellow solid (120mg, 83%) and be directly used in next step with reversed-phase preparative chromatography.Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 7.97 (s, 1H), 4.45-4.42 (m, 2H), 3.92 (s, 1H), 3.85 (s, 2H), 3.23 (t, J=6.8Hz, 2H), 2.90 (s, 2H), 1.95-1.93 (m, 2H), 1.51-1.49 (m, 2H), 1.26 (s, 6H).
3) product A 34 is synthetic:
A34-2 (120mg, 0.46mmol), cesium fluoride (156mg, 1.02mmol) and A1-9(129mg, 0.51mmol) under agitation condition, be dissolved in methyl-sulphoxide (1mL) respectively, be heated to 120 ℃, react 24 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methyl alcohol: methylene dichloride=1:25) a colorless oil, place in air and within 24 hours, change yellow solid into, purifying obtains white solid (10mg, 4.4%) again.Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.99 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 8.09 (s, 1H), 7.44 (s, 1H), 4.51-4.48 (m, 2H), 4.07 (s, 2H), 4.01 (br s, 1H), 3.51 (t, J=6.4Hz, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 1.99-1.97 (m, 2H), 1.59-1.57 (m, 2H), 1.35 (s, 6H); ESI-MS (m/z): 492.8[M+1]
+.
The oily matter spectrum analysis of gained is
Embodiment 35
The present embodiment provides a kind of new antitumoral compounds A35, and the synthetic method of this compound is as follows:
1) intermediate A 1-2's is synthetic:
4-tertbutyloxycarbonyl piperidone (2g, 10.1mmol) and DMF dimethylacetal (18g, 151.5mmol) are stirred, and 90 ℃ are reacted 12 hours.Be cooled to room temperature, join in ethyl acetate (150mL) and water (50mL), saturated aqueous common salt for organic phase (50mL) washes twice, and anhydrous sodium sulfate drying filters, and revolves and steams to such an extent that an orange crude product (3.10g) is directly cast single step reaction.
2) intermediate A 35-1's is synthetic:
Under normal temperature, by Guanidinium hydrochloride (1.92g, 20.1mmol) and sodium ethylate (1.37g, 20.1mmol) be dissolved in ethanol (20mL), stir after half an hour, add the synthetic intermediate A 1-2 (3.10g of step, 12.2mmol), backflow reaction overnight.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, evaporated under reduced pressure, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=2:1) an orange (750mg, 25%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.05 (s, 1H), 4.95 (s, 2H), 4.44 (s, 2H), 3.69 (t, J=5.8Hz, 2H), 2.75 (t, J=5.4Hz, 2H), 1.49 (s, 9H).
3) intermediate A 35-2's is synthetic:
By A35-1 (750mg, 3.0mmol) be dissolved in after the ethyl acetate of 3M, the saturated ethyl acetate solution (5mL) that adds hydrogenchloride, stirring at normal temperature 3 hours, desolventizing is revolved in decompression, and solute joins in saturated sodium bicarbonate aqueous solution in (5mL) and methylene dichloride (20mL), organic phase is washed with saturated common salt, anhydrous sodium sulfate drying is spin-dried for to obtain a white solid (350mg, 78%) after filtering.
4) product A 35 is synthetic:
A35-2 (50mg, 0.3mmol), cesium fluoride (125mg, 0.8mmol) and A1-9 (127mg, 0.5mmol) are dissolved in methyl-sulphoxide (1mL) respectively under agitation condition, are heated to 120 ℃, react 36 hours.Be cooled to room temperature, add ethyl acetate (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute through column chromatography refining (moving phase is methylene dichloride: methyl alcohol=50:1) a yellow solid (80mg, 66%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.35 (s, 1H), 8.23 (s, 2H), 8.10 (s, 1H), 7.43 (s, 1H), 6.65 (s, 1H), 4.94 (s, 2H), 4.56 (s, 2H), 3.90 (t, J=5.8Hz, 2H), 2.87 (t, J=5.8Hz, 2H), 2.37 (s, 3H), 2.17 (s, 3H); ESI-MS (m/z): 366.8[M+1]
+.
The solid of gained is through resolving to
Embodiment 36
The present embodiment provides a kind of new antitumoral compounds A36, and the synthetic method of this compound is as follows:
A6(40mg, 0.090mmol) room temperature is placed in air three days, and with preparing plate, (developping agent is sherwood oil to mixture: ethyl acetate=1:2) purifying obtains white solid (2mg, 5%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.89 (s, 1H), 8.46 (s, 1H), 8.34 (s, 1H), 8.02 (s, 1H), 7.44 (s, 1H), 4.50-4.46 (m, 2H), 4.32 (t, J=7.0Hz, 2H), 4.01 (br s, 2H), 3.53 (t, J=10.0Hz, 2H), 3.02 (t, J=6.4Hz, 2H), 2.37 (s, 3H), 2.23 (s, 3H), 2.00-1.97 (m, 2H), 1.57-1.50 (m, 2H); ESI-MS (m/z): 464.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 37
The present embodiment provides a kind of new antitumoral compounds A37, and the synthetic method of this compound is as follows:
1) intermediate A 37-1's is synthetic:
2,5-bis-chloro-4-boric acid pyridine (671mg, 3.5mmol) and 5-methyl-2-bromopyridine (500mg, 2.9mmol) are joined in the mixed solution of 5 milliliters of dioxane and 2 ml waters, then add Pd (dppf) Cl
2(212mg, 0.29mmol) and three water potassiumphosphates (1.16g, 4.35mmol), nitrogen exchange three times for reaction system, reflux is spent the night.Reaction solution cool to room temperature, adds 10 ml waters to filter, and filtrate extracts three times with methylene dichloride (10mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: ethyl acetate=50:1) obtain white solid (100mg, 15%).
1H-NMR(400MHz,CDCl
3):δ8.59(s,1H),8.47(s,1H),7.69-7.63(m,3H),2.44(s,3H)。
2) product A 37 is synthetic:
Respectively by A37-1 (30mg, 0.13mmol), A3-2(24mg, 0.13mmol) and C
sf(38mg, 0.25mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 24h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is methylene dichloride to solute: methyl alcohol=50:1), obtain a yellow solid (20mg, 39%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.54 (s, 1H), 8.25 (s, 1H), 8.18 (s, 1H), 7.64-7.59 (m, 2H), 6.96 (s, 1H), 5.82 (br s, 1H), 4.58 (s, 2H), 3.92 (t, J=5.6Hz, 2H), 2.88 (t, J=5.6Hz, 2H), 2.77 (br s, 1H), 2.42 (s, 3H), 0.81 (s, 2H), 0.54 (s, 2H); ESI-MS (m/z): 392.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 38
The present embodiment provides a kind of new antitumoral compounds A38, and the synthetic method of this compound is as follows:
1) intermediate A 38-1's is synthetic
In the three-necked bottle of a 25mL, add respectively the bromo-3-picoline of 2-(500mg, 2.82mmol), A1-8 (700mg, 3.64mmol), K
3pO
4.3H
2o (1.50g, 5.64mmol), Pd (dppf) Cl
2(103mg, 0.140mmol) and Isosorbide-5-Nitrae-dioxane/water (7:1,10mL), with after nitrogen replacement three times, be heated to 100 ℃, reaction 16h, be chilled to room temperature, filter, filtrate is spin-dried for, and with column chromatography, refining (moving phase is sherwood oil: ethyl acetate=20:1), obtain a white solid (40mg, 6%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.55 (d, J=4.4Hz, 1H), 8.48 (s, 1H), 7.65 (d, J=7.6Hz, 1H), 7.34 (s, 1H), 7.33-7.31 (m, 1H), 2.20 (s, 3H).
2) product A 38 is synthetic
Respectively by A38-1 (40mg, 0.17mmol), A3-2(50mg, 0.26mmol) and C
sf(64mg, 0.43mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (2mg, 3%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.53 (d, J=4.4Hz, 1H), 8.25 (s, 1H), 8.17 (s, 1H), 7.62 (d, J=7.6Hz, 1H), 7.29-7.28 (m, 1H), 5.28 (s, 1H), 4.56 (s, 2H), 3.99-3.83 (m, 2H), 2.89 (t, J=11.2Hz, 2H), 2.83-2.73 (m, 1H), 2.21 (s, 3H), 0.85-0.78 (m, 2H), 0.59-0.48 (m, 2H); ESI-MS (m/z): 392.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 39
The present embodiment provides a kind of new antitumoral compounds A39, and the synthetic method of this compound is as follows:
1) intermediate A 39-1's is synthetic:
By 2, the chloro-4-boric acid of 5-bis-pyridine (550mg, 2.9mmol) with 2-bromoquinoline (500mg, 2.3mmol) join in the mixed solution of 2.4 milliliters of 2N solution of potassium carbonate, 5 milliliters of ethanol and 5 milliliters of toluene, then add tetra-triphenylphosphine palladium (275mg, 0.24mmol), nitrogen exchange three times for reaction system, tube sealing is heated to 105 ℃.Reaction solution cool to room temperature, adds 10 ml waters to filter, and filtrate extracts three times with methylene dichloride (10mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: ethyl acetate=25:1) obtain white solid (210mg, 32%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3): δ 8.52 (s, 1H), 8.31 (d, J=8.4Hz, 1H), 8.18 (d, J=8.8Hz, 1H), 7.92 (d, J=8.0Hz, H), 7.81-7.79 (m, 2H), 7.76 (s, 1H), 7.66 (t, J=7.2Hz, 1H).
2) product A 39 is synthetic:
Respectively by A39-1 (40mg, 0.15mmol), A3-2(37mg, 0.15mmol) and C
sf(44mg, 0.29 mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 24h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is methylene dichloride to solute: methyl alcohol=50:1), obtain a light yellow solid (20mg, 32%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.23 (s, 1H), 8.19 (d, J=8.4Hz, 1H), 8.14-8.12 (m, 2H), 7.83 (d, J=8.4Hz, 1H), 7.71-7.68 (m, 2H), 7.55 (d, J=7.2Hz, 1H), 6.97 (s, 1H), 5.39 (br s, 1H), 4.54 (s, 2H), 3.89 (t, J=5.6Hz, 2H), 2.83 (t, J=5.6Hz, 2H), 2.69 (br s, 1H), 0.76-0.74 (m, 2H), 0.46 (s, 2H); ESI-MS (m/z): 428.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 40
The present embodiment provides a kind of new antitumoral compounds A40, and the synthetic method of this compound is as follows:
1) intermediate A 40-1's is synthetic
In the three-necked bottle of a 25mL, add respectively 2-bromopyridine (100mg, 0.63mmol), A1-8 (240mg, 1.25mmol), K
2cO
3(175mg, 1.27mmol), Pd (dppf) Cl
2(50mg, 0.068mmol) and glycol dimethyl ether/water (7:1,5mL), with after nitrogen replacement three times, be heated to 90 ℃, reaction 4h, is chilled to room temperature, filters, filtrate is spin-dried for, with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=2:1), obtain a white solid (45mg, 32%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.77 (d, J=4.4Hz, 1H), 8.48 (s, 1H), 7.86-7.82 (m, 1H), 7.76 (d, J=8.0Hz, 1H), 7.66 (s, 1H), 7.42-7.39 (m, 1H).
2) product A 40 is synthetic
Respectively by A40-1 (45mg, 0.20mmol), A3-2 (60mg, 0.32mmol) and C
sf(100mg, 0.67mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (8mg, 14%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.75 (d, J=4.8Hz, 1H), 8.27 (s, 1H), 8.20 (s, 1H), 7.83-7.79 (m, 1H), 7.72 (d, J=8.0Hz, 1H), 7.38-7.35 (m, 1H), 6.97 (s, 1H), 5.24 (s, 1H), 4.59 (s, 2H), 3.94 (t, J=11.6Hz, 2H), 2.89 (t, J=11.6Hz, 2H), 2.80-2.74 (m, 1H), 0.85-0.80 (m, 2H), 0.55-0.52 (m, 2H); ESI-MS (m/z): 378.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 41
The present embodiment provides a kind of new antitumoral compounds A41, and the synthetic method of this compound is as follows:
1) intermediate A 41-1's is synthetic
In the three-necked bottle of a 25mL, add respectively the bromo-5-5-flumethiazine of 2-(100mg, 0.44mmol), A1-8 (150mg, 0.78mmol), K
3pO
4.3H
2o (230mg, 0.86mmol), Pd (dppf) Cl
2(32mg, 0.044mmol) and tetrahydrofuran (THF)/water (7:1,5mL), with after nitrogen replacement three times, be heated to 60 ℃, reaction 16h, is chilled to room temperature, filters, filtrate is spin-dried for, and with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (43mg, 33%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 9.03 (s, 1H), 8.52 (s, 1H), 8.09 (d, J=8.0Hz, 1H), 7.91 (d, J=8.0Hz, 1H), 7.67 (s, 1H).
2) product A 41 synthetic
Respectively by A41-1 (43mg, 0.15mmol), A3-2(40mg, 0.21mmol) and C
sf(70mg, 0.47mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (11mg, 17%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 9.04 (s, 1H), 8.75-8.71 (m, 1H), 8.65 (d, J=2.0Hz, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 6.96 (s, 1H), 5.48 (br s, 1H), 4.60 (s, 2H), 3.95 (t, J=12.0Hz, 2H), 2.92 (t, J=12.0Hz, 2H), 2.78-2.77 (m, 1H), 0.85-0.81 (m, 2H), 0.56-0.53 (m, 2H); ESI-MS (m/z): 446.8[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 42
The present embodiment provides a kind of new antitumoral compounds A42, and the synthetic method of this compound is as follows:
1) intermediate A 42-1's is synthetic:
By 2, the chloro-4-boric acid of 5-bis-pyridine (290mg, 1.5mmol) with 2-bromo pyrimi piperidine (200mg, 1.26mmol) join in the mixed solution of 1.3 milliliters of 2N solution of potassium carbonate, 3 milliliters of ethanol and 3 milliliters of toluene, then add tetra-triphenylphosphine palladium (146mg, 0.13mmol), nitrogen exchange three times for reaction system, tube sealing is heated to 115 ℃.Reaction solution cool to room temperature, adds 5 ml waters to filter, and filtrate extracts three times with methylene dichloride (10mL), and organic phase is filtered with anhydrous sodium sulfate drying, and filtrate was spin-dried for post (sherwood oil: ethyl acetate=25:1) obtain white solid (60mg, 21%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3): δ 8.86 (d, J=4.8Hz, 2H), 8.45 (s, 1H), 7.73 (s, 1H), 7.33 (t, J=4.8Hz, 1H).
2) product A 42 is synthetic:
Respectively by A42-1 (20mg, 0.09mmol), A3-2(17mg, 0.09mmol) and C
sf(27mg, 0.18mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 24h, is chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is methylene dichloride to solute: methyl alcohol=100:1), obtain a light yellow solid (7mg, 20%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.97 (d, J=4.8Hz, 2H), 8.31 (s, 1H), 8.20 (s, 1H), 7.37 (t, J=4.8Hz, 1H), 7.08 (s, 1H), 5.29 (br s, 1H), 4.59 (s, 2H), 3.94 (t, J=6.0Hz, 2H), 2.90 (t, J=5.6Hz, 2H), 2.77 (br s, 1H), 0.84-0.80 (m, 2H), 0.54 (s, 2H); ESI-MS (m/z): 380.1[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 43
The present embodiment provides a kind of new antitumoral compounds A43, and the synthetic method of this compound is as follows:
1) intermediate A 43-1's is synthetic
In the tube sealing of a 25mL, add respectively 2-chloropyrazine (100mg, 0.87mmol), A1-8 (340mg, 1.77mmol), Na
2cO
3(185mg, 1.74mmol), Pd (PPh
3)
4(170mg, 0.15mmol) and Isosorbide-5-Nitrae-dioxane/water (7:1,5mL), with nitrogen, blow 10min, be heated to 130 ℃, reaction 16h, be chilled to room temperature, filter, filtrate is spin-dried for, and with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (35mg, 18%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 9.09 (s, 1H), 8.78-8.75 (m, 1H), 8.70 (d, J=2.4Hz, 1H), 8.54 (s, 1H), 7.69 (s, 1H).
2) product A 43 is synthetic
Respectively by A43-1 (35mg, 0.15mmol), A3-2(40mg, 0.21mmol) and C
sf(70mg, 0.47mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (10mg, 17%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 9.02 (s, 1H), 8.30 (s, 1H), 8.22 (s, 1H), 8.05 (d, J=8.0Hz, 1H), 7.88 (d, J=8.0Hz, 1H), 6.98 (s, 1H), 5.88 (br s, 1H), 4.62 (s, 2H), 3.95 (t, J=11.2Hz, 2H), 296 (t, J=11.2Hz, 2H), 2.83-2.77 (m, 1H), 0.87-0.83 (m, 2H), 0.60-0.56 (m, 2H); ESI-MS (m/z): 379.9[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 44
The present embodiment provides a kind of new antitumoral compounds A44, and the synthetic method of this compound is as follows:
1) intermediate A 44-1's is synthetic
After glycol dibromide (40mg, 0.21mmol) being added in the tetrahydrofuran (THF) suspension of zinc, be heated to 50 ℃, after 5min, add successively TMSCl(20mg, 0.18mmol) and the tetrahydrofuran solution (1mL) of 2-bromo thiazole, 50 ℃ of reaction 1h.The tetrahydrofuran solution of prepared 2-bromo thiazole zincon is injected to the chloro-4-iodine pyridine of 2,5-bis-(300mg, 1.09mmol) and Pd (PPh
3)
4in the tetrahydrofuran solution of (40mg, 0.035mmol) (10mL), be heated to reflux, after reaction 12h, be chilled to room temperature, filter, filtrate is spin-dried for, with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (60mg, 24%).Its chemical shift is as follows:
1h-NMR (300MHz, CDCl
3) δ 8.53 (s, 1H), 8.51 (s, 1H), 8.08-8.07 (m, 1H), 7.68-7.67 (m, 1H).
2) product A 44 is synthetic
Respectively by A44-1 (50mg, 0.22mmol), A3-2(50mg, 0.26mmol) and C
sf(130mg, 0.85mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (8mg, 10%).Its chemical shift is as follows:
1h-NMR (300MHz, CDCl
3) δ 8.31 (s, 1H), 8.24 (s, 1H), 8.02 (d, J=3.0Hz, 1H), 7.62 (s, 1H), 7.61 (d, J=3Hz, 1H), 5.70 (br s, 1H), 4.63 (s, 2H), 3.98 (t, J=11.2Hz, 2H), 2.99-2.93 (m, 2H), 2.83-2.75 (m, 1H), 0.87-0.81 (m, 2H), 0.61-0.50 (m, 2H).
The solid spectrum analysis of gained is
Embodiment 45
The present embodiment provides a kind of new antitumoral compounds A45, and the synthetic method of this compound is as follows:
After being dissolved in to Isosorbide-5-Nitrae-dioxane (1mL), A35 (50mg, 0.1mmol) adds N, N-diisopropylethylamine (53mg, 0.4mmol) adds Vinyl chloroformate (18mg under agitation condition, 0.2mmol), be heated to 100 ℃, reaction overnight.Be cooled to room temperature, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute, through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1), obtains a yellow solid (20mg, 33%).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.40 (s, 1H), 8.35 (s, 1H), 8.24 (s, 1H), 7.60 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 4.66 (s, 2H), 4.28 (m, 2H), 3.93 (s, 2H), 3.02 (s, 2H), 2.38 (s, 3H), 2.17 (s, 3H), 1.32 (t, J=7.0Hz, 3H).
The solid spectrum analysis of gained is
Embodiment 46
The present embodiment provides a kind of new antitumoral compounds A46, and the synthetic method of this compound is as follows:
After A35 (50mg, 0.1mmol) is dissolved in to anhydrous tetrahydro furan (1mL) with sodium hydride (33mg, 1.4mmol), stir 30 minutes, under agitation condition, add ethyl isocyanate (48.5mg, 0.7mmol).At normal temperatures after reaction overnight, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute obtains a yellow solid (15mg, 25%) through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1).Its chemical shift is as follows:
1h-NMR (400MHz, CDCl
3) δ 8.92 (s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 8.25 (s, 1H), 7.45 (s, 1H), 7.30 (s, 1H), 6.69 (s, 1H), 4.65 (s, 2H), 3.93 (s, 2H), 3.41 (t, J=6.4Hz, 2H), 2.98 (d, J=2.6Hz, 2H), 2.39 (s, 3H), 2.18 (s, 3H), 1.24 (t, J=7.0Hz, 3H).
The solid spectrum analysis of gained is
Embodiment 47
The present embodiment provides a kind of new antitumoral compounds A47, and the synthetic method of this compound is as follows:
After A35 (50mg, 0.1mmol) is dissolved in to anhydrous tetrahydro furan (1mL) with sodium hydride (8mg, 0.7mmol), stir 30 minutes, under agitation condition, add n-Isopropyl isocyanate (58.10mg, 0.3mmol).At normal temperatures after reaction overnight, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute obtains a yellow solid (11mg, 17%) through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1).Its chemical shift is as follows:
1h-NMR (300MHz, CDCl
3) δ 8.87 (s, 1H), 8.35 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.44 (s, 1H), 7.39 (s, 1H), 6.68 (s, 1H), 4.64 (s, 2H), 4.08 (m, 1H), 3.93 (t, J=5.7Hz, 2H), 2.96 (t, J=5.4Hz, 2H), 2.38 (s, 3H), 2.18 (s, 3H), 1.26 (d, J=3Hz, 6H).
The solid spectrum analysis of gained is
Embodiment 48
The present embodiment provides a kind of new antitumoral compounds A48, and the synthetic method of this compound is as follows:
1) intermediate A 48-1's is synthetic
In the three-necked bottle of a 25mL, add respectively 3-bromopyridine (100mg, 0.63mmol), A1-8 (240mg, 1.25mmol), Na
2cO
3(135mg, 1.27mmol), Pd (dppf) Cl
2(45mg, 0.061mmol) and glycol dimethyl ether/water (7:1,5mL), with after nitrogen replacement three times, be heated to 100 ℃, reaction 16h, is chilled to room temperature, filters, filtrate is spin-dried for, with column chromatography, refining (moving phase is sherwood oil: methylene dichloride=3:2), obtain a white solid (30mg, 21%).
1H-NMR(300MHz,CDCl
3)δ8.72(s,2H),8.50(s,1H),7.84-7.81(m,1H),7.46-7.42(m,1H),7.35(s,1H)。
2) product A 48 is synthetic
Respectively by A48-1 (30mg, 0.13mmol), A3-2(40mg, 0.21mmol) and C
sf(80mg, 0.53mmol) be dissolved in 1mL methyl-sulphoxide, be heated to 120 ℃, reaction 12h, be chilled to room temperature, with ethyl acetate and water extraction, organic phase is dry to be spin-dried for, with column chromatography, refining (moving phase is sherwood oil to solute: ethyl acetate=1:1), obtain a yellow solid (10mg, 20%).Its chemical shift is as follows:
1h-NMR (300MHz, CDCl
3) δ 8.70 (s, 1H), 8.27 (s, 1H), 8.22 (s, 1H), 7.83 (d, J=8.1Hz, 1H), 7.43-7.39 (m, 1H), 6.64 (s, 1H), 5.74 (br s, 1H), 4.59 (s, 2H), 3.93 (t, J=11.2Hz, 2H), 2.94 (t, J=11.7Hz, 2H), 2.82-2.76 (m, 1H), 0.87-0.81 (m, 2H), 0.59-0.54 (m, 2H); ESI-MS (m/z): 378.9[M+1]
+.
The solid spectrum analysis of gained is
Embodiment 49
The present embodiment provides a kind of new antitumoral compounds A49, and the synthetic method of this compound is as follows:
After being dissolved in to Isosorbide-5-Nitrae-dioxane (1mL), A35 (50mg, 0.1mmol) adds N, N-diisopropylethylamine (88.11mg, 0.7mmol) adds trimethyl-acetyl chloride (49.43mg under agitation condition, 0.4mmol), be heated to 100 ℃, reaction overnight.Be cooled to room temperature, add methylene dichloride (20mL) and water (10mL), saturated aqueous common salt for organic phase (10mL) is washed, after anhydrous sodium sulfate drying filters, revolve desolventizing, solute obtains a yellow solid (20mg, 32%) through column chromatography refining (moving phase is ethyl acetate: sherwood oil=1:1 is to 3:1).Its chemical shift is as follows:
1h-NMR (300MHz, CDCl
3) δ 8.40 (s, 1H), 8.35 (s, 1H), 8.24 (s, 1H), 8.06 (s, 1H), 7.43 (s, 1H), 6.68 (s, 1H), 4.67 (s, 2H), 3.93 (t, J=5.7Hz, 2H), 3.04 (t, J=5.8Hz, 2H), 2.38 (s, 3H), 2.17 (s, 3H), 1.33 (s, 9H).
The solid spectrum analysis of gained is
Embodiment 50
The present embodiment carries out biological NIH3T3-GRE-Luc luciferase reporter gene test experience to the compound of embodiment 1-49 gained, the barrier effect of checking gained compound to hedgehog path Hedgehog (Hh).
NIH3T3 cell be the DMEM that contains 10%FBS (Hyclone) (11965, cultivate in Gibico).GRE-firefly luciferin plasmid is to implant in MCS and obtain via the cell transcription factor GLI-1 response element that amplifies octuple.Mono-clonal is through restructuring Su Nike hedgehog path albumen and small molecules agonist SAG checking.The selected clone who is verified is for detection of hedgehog path signal.The NIH3T3 cell of expressing GRE-Lampyridea element is to maintain in complete nutrient solution.When needs are done analyzing and testing, cell is added in 96 orifice plates, and final every hole is containing cell approximately 15,000.96 orifice plates are being cultivated 48 hours.Detected compound is by DMSO and detect damping fluid by serial dilution.10nMSAG is as hedgehog path agonist.The analysis buffer that 100 microlitres include test compound and agonist subsequently carefully joins and contains in cell in 96 orifice plates, and cultivates 48 hours at 37 degrees Celsius.After cultivating 48 hours, 40 microlitre Photinus pyralis LUCs are added in each hole.96 orifice plates are jog 5 minutes at room temperature.Luminous signal is by reading plate device record.The activity of compound is calculated by its blocking-up to luminous signal.The present embodiment according to above-mentioned NIH3T3-GRE-Luc luciferase reporter gene test experience, choosing small molecules SMO antagonist GDC-0449 is control drug, biological activity to the compd A 1-A49 in embodiment is measured, experimental result is as shown in the table: experimental result shows, the IC50 of some of them compound is better than control drug.
As seen from the above-described embodiment, the antineoplastic compound of the embodiment of the present invention, by blocking-up transmembrane protein acceptor SMO, can be blocked hedgehog path Hedgehog, thereby suppress cellular abnormality, increases, and blocking-up tumour cell shifts regeneration.
The present invention still has numerous embodiments, and all employing equivalents or equivalent transformation and all technical schemes of forming, within all dropping on protection scope of the present invention.
Claims (11)
1. pyrimidine skeleton has a new antitumoral compounds for hedgehog path antagonistic activity, comprises this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, has the structure shown in general formula I:
Wherein, X is five yuan or hexa-atomic aromatic nucleus, fragrant heterocycle, heterocycle, and the substitutive derivative of described ring, n is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
2. a kind of pyrimidine skeleton according to claim 1 has the new antitumoral compounds of hedgehog path antagonistic activity, this compound and pharmacy acceptable salt thereof, various isotropic substance, various isomer or various crystalline structure, comprise general formula I I or general formula III structure:
Wherein: A is nitrogen-atoms or C-R7, n is 0,1,2,3,4,5 or 6, R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, halogen, alkane is for halogen, cyano group, alkane is for cyano group, trifluoromethyl, alkyl, thiazolinyl, alkynyl, amino, O, hydroxyl, S, sulfydryl, alkoxyl group, fat base, amide group, urea groups, oxo urea groups, thioureido, sulfuryl, sulfoxide group, sulfahydantoin, azido-, alkane is for thiazolinyl, alkane is for alkynyl, alkane is for amino, alkane is for hydroxyl, alkane is for fat base, alkane is for sulfuryl, alkane is for sulfoxide group, alkane is for sulfahydantoin, alkane is for azido-, cyclic alkyl, ring-type thiazolinyl, 3-12 heterocycle, aromatic nucleus or 5-12 virtue heterocycle or the substituting group of rolling into a ball containing heteroatom functional.
3. a kind of pyrimidine skeleton according to claim 2 has the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that:
Described alkyl is alkyl or the substituted hydrocarbon radical of saturated straight chain, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described thiazolinyl is alkyl or the substituted hydrocarbon radical of the straight chain that contains at least one carbon-carbon double bond, side chain, ring-type, double-ring or the Spirocyclic of 1-10 carbon atom composition;
Described alkynyl is alkyl or the substituted hydrocarbon radical of the straight chain, side chain, ring-type, double-ring or the Spirocyclic that contain at least one carbon carbon triple bond of 1-10 carbon atom composition;
The substituting group of the monocycle that described fragrant cyclic group is aromaticity, many rings or heterocyclic substituent and substitutive derivative thereof, and the cyclic substituents derivative with saturated rings;
Described heterocyclic radical is monocycle, dicyclo, three ring or the volution substituting groups of the nonaromatic combination that comprises an atom in nitrogen, oxygen and sulphur or a plurality of atoms, and the cyclic substituents of their various oxidation state;
The described substituting group containing heteroatom functional group is the halogeno-group containing F, Cl, Br or I or the substituting group that comprises the one or more atoms in nitrogen, oxygen, sulphur and phosphorus, and their various oxidation state, and the quaternary ammonium salt of nitrogen.
4. a kind of pyrimidine skeleton according to claim 2 has the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that: described R1, R2, R3, R4, R5, R6, R7 is independently selected from respectively: hydrogen atom, alkyl, thiazolinyl, alkynyl, fragrant cyclic group or heterocyclic radical that hydrogen atom is replaced by halogeno-group, cyano group, amino, hydroxyl, sulfydryl, alkoxyl group, ester group, sulfuryl, sulfoxide group, sulfahydantoin or azido-, and cyclic alkyl, ring-type thiazolinyl, 3-12 unit's heterocyclic radical or 5-12 membered aromatic heterocycle base; The alkyl that described hydrogen atom is replaced by halogeno-group is preferably trifluoromethyl.
5. according to a kind of pyrimidine skeleton described in claim 1-4 any one, there is the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that: the structure of X is any one in lower array structure:
6. according to a kind of pyrimidine skeleton described in claim 1-5 any one, there is the new antitumoral compounds of hedgehog path antagonistic activity, it comprises following compounds, and pharmacy acceptable salt, various isotropic substance, various isomer or various crystalline structure:
7. a kind of pyrimidine skeleton according to claim 6 has the new antitumoral compounds of hedgehog path antagonistic activity, it is characterized in that: the methylamino in compound or substituted methylamine base replace with any one in following amine and analogue thereof:
8. according to a kind of pyrimidine skeleton described in claim 1-7 any one, have the new antitumoral compounds of hedgehog path antagonistic activity, it comprises following compound:
9. an antitumor medicine composition, comprises the combination that at least two kinds of compounds in new antitumoral compounds, its pharmacy acceptable salt, various isotropic substance, various isomer or the various crystalline structure that the pyrimidine skeleton with formula I structure described in claim 1-8 has hedgehog path antagonistic activity form.
10. a combined utilization composition for antitumor drug, this combined utilization composition be the pyrimidine skeleton described in claim 1-8 have the new antitumoral compounds of hedgehog path antagonistic activity and pharmaceutical composition thereof respectively with cis-platinum, taxol, camptothecine, Herceptin, imatinib mesylate, imatinib, Gefitinib, erlotinib, lapatinibditosylate in one or more combination carry out the composition that combined utilization obtains.
The application of the combined utilization composition of new antitumoral compounds, antitumor medicine composition or antitumor drug that pyrimidine skeleton described in 11. 1 kinds of claim 1-10 has a hedgehog path antagonistic activity in the medicine of preparation treatment tumour, described tumour comprises liver cancer, lung cancer, the rectum cancer, cervical cancer, cancer of pancreas, breast cancer, cancer of the stomach, oral carcinoma, the esophageal carcinoma, nasopharyngeal carcinoma, skin carcinoma, osteocarcinoma, the combination of one or more in kidney and leukemia.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310463448.2A CN103694236B (en) | 2013-01-15 | 2013-10-08 | A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist |
| EP13871618.8A EP2945623B1 (en) | 2013-01-15 | 2013-12-20 | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
| PCT/US2013/077305 WO2014113191A1 (en) | 2013-01-15 | 2013-12-20 | Hedgehog pathway signaling inhibitors and therapeutic applications thereof |
| US14/761,166 US9695178B2 (en) | 2013-01-15 | 2013-12-20 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310014254.4 | 2013-01-15 | ||
| CN201310014254 | 2013-01-15 | ||
| CN2013100142544 | 2013-01-15 | ||
| CN201310463448.2A CN103694236B (en) | 2013-01-15 | 2013-10-08 | A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103694236A true CN103694236A (en) | 2014-04-02 |
| CN103694236B CN103694236B (en) | 2017-05-31 |
Family
ID=50079123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310463448.2A Active CN103694236B (en) | 2013-01-15 | 2013-10-08 | A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist |
| CN201310465383.5A Active CN103588771B (en) | 2013-01-15 | 2013-10-08 | There is the miazines antineoplastic compound of activity of hedgehog path antagonist |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310465383.5A Active CN103588771B (en) | 2013-01-15 | 2013-10-08 | There is the miazines antineoplastic compound of activity of hedgehog path antagonist |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103694236B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790156A (en) * | 2016-07-04 | 2019-05-21 | 苏州开拓药业股份有限公司 | Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
| WO2024208265A1 (en) * | 2023-04-04 | 2024-10-10 | 苏州开拓药业股份有限公司 | Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| UA125503C2 (en) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| WO2014172644A2 (en) | 2013-04-19 | 2014-10-23 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP3124482B1 (en) | 2014-03-24 | 2019-09-11 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Quinoline derivatives as smo inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| UA121669C2 (en) | 2015-02-20 | 2020-07-10 | Інсайт Корпорейшн | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| CN112566912A (en) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Salts of FGFR inhibitors |
| SI3788047T1 (en) | 2018-05-04 | 2024-11-29 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4045151A1 (en) | 2019-10-14 | 2022-08-24 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202128686A (en) * | 2019-10-25 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | A fused heteroaryl derivative, a preparation method and medical use thereof |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4069695A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN120936354A (en) * | 2023-04-04 | 2025-11-11 | 苏州开拓药业股份有限公司 | Use of a heterocyclic compound in the treatment of interstitial pneumonia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073772A1 (en) * | 2007-12-06 | 2009-06-11 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| WO2012052390A1 (en) * | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2630134B9 (en) * | 2010-10-20 | 2018-04-18 | Pfizer Inc | Pyridine-2- derivatives as smoothened receptor modulators |
-
2013
- 2013-10-08 CN CN201310463448.2A patent/CN103694236B/en active Active
- 2013-10-08 CN CN201310465383.5A patent/CN103588771B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009073772A1 (en) * | 2007-12-06 | 2009-06-11 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| WO2012052390A1 (en) * | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | N-2-(2-pyridinyl)-4-pyrimidinyl-beta-alanine derivatives as inhibitors of histone demethylase jmjd3 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790156A (en) * | 2016-07-04 | 2019-05-21 | 苏州开拓药业股份有限公司 | Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof |
| CN113651816A (en) * | 2016-07-04 | 2021-11-16 | 苏州开拓药业股份有限公司 | Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof |
| CN113651816B (en) * | 2016-07-04 | 2022-09-23 | 苏州开拓药业股份有限公司 | Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof |
| US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
| US12365668B2 (en) | 2018-03-08 | 2025-07-22 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-y inhibitors |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US12421197B2 (en) | 2018-07-02 | 2025-09-23 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2024208265A1 (en) * | 2023-04-04 | 2024-10-10 | 苏州开拓药业股份有限公司 | Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103694236B (en) | 2017-05-31 |
| CN103588771A (en) | 2014-02-19 |
| CN103588771B (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103694236A (en) | Novel antineoplastic compound containing pyrimidine skeleton and hedgehog pathway antagonist activity | |
| ES2502941T3 (en) | Method of preparation of dihydroindene amide compounds, pharmaceutical compositions containing said compounds and use as a protein kinase inhibitor | |
| ES2368876T3 (en) | DERIVATIVES OF 2-HETEROARILAMINOPIRIMIDINA AS KINASE INHIBITORS. | |
| JP7451765B2 (en) | Pyridine acetamide derivatives as CDK inhibitors, their preparation methods and uses | |
| AU2016271762B2 (en) | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | |
| CN101568529A (en) | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections | |
| CN105503827B (en) | EGFR inhibitor and its preparation method and application | |
| CN101568530A (en) | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors | |
| CN109311900A (en) | Monofunctional intermediates for ligand-dependent degradation of target proteins | |
| EA023350B1 (en) | Antimicrobial compounds, methods of making and using the same | |
| KR20190141215A (en) | N- (azaryl) cyclolactam-1-carboxamide derivatives, synthesis methods and uses thereof | |
| CN108699055A (en) | Heterocyclic compound as anticancer drug | |
| CN119110801A (en) | Fluoroquinoxalinone derivatives that selectively inhibit PARP1 | |
| CN108602818A (en) | Pyrazole fused ring analog derivative, preparation method and its application in treating cancer, inflammation and immunity disease | |
| CA2692922A1 (en) | Azaindole-indole coupled derivatives, preparation methods and uses thereof | |
| JP2024505732A (en) | Pyridopyrimidinone derivatives and their production methods and uses | |
| CN103923085B (en) | Pyridine-heterocyclic compound with activity of hedgehog path antagonist and application thereof | |
| KR20170106294A (en) | Six-membered ring benzo deribatibes as dpp-4 inhibitor and use thereof | |
| WO2011133444A1 (en) | Substituted pyrimidines | |
| JP2021070688A (en) | Pharmaceutical composition for prevention and/or treatment of hearing loss | |
| CA2892927A1 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
| CN115466289A (en) | Compounds with TYK2 inhibitory activity, pharmaceutical compositions containing them, and applications thereof | |
| CN109422737A (en) | Imidazolone androgen receptor antagonists, preparation method and use | |
| KR20200013702A (en) | Ligand Compounds of α7 Nicotinic Acetylcholine Receptor and Their Applications | |
| CN116406363A (en) | Tetracyclic derivative, preparation method and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170426 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY standing building C4-401 Applicant after: Suzhou pharmaceutical Limited by Share Ltd Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215123 Xinghu Street No. 218 BioBAY A1 North Building 2 floor E36 room Applicant before: SUZHOU YUNXUAN PHARMACEUTICAL CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |